Teleflex Inc (TFX)

Teleflex Initiates Enrollment in Global BIOMAG™-III Pivotal Trial of Freesolve™ Resorbable Magnesium ScaffoldJune 23, 2026 6:30 AM
Business Wire Enrollment completed ahead of schedule in BIOMAG™-II Positive four-year BIOMAG™-I results recently reported Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™-III Study (NCT07258290), a landmark global study evaluating the Freesolve™ Resorbable Magnesium Scaffold (RMS). Dr. Itsik Ben-Dor, MedStar Health in Washington, D.C., is the first implanter in the United States (U.S.) in the IDE trial of Freesolve™ RMS. Designed as a pivotal trial to support future regulatory applications, the BIOMAG™-III Study represents the most comprehensive planned clinical evaluation of Freesolve™ RMS to date. Chairman of the steering committee of the BIOMAG™-III Study, Dr. Ron Waksman?, Associate Director of Cardiology at MedStar Washington Hospital Center, stated: “I’m proud that the very first patient in the BIOMAG™-III IDE trial has been enrolled at MedStar Health. Contributing to this important international study is the first step towards potentially changing how we treat narrowed arteries, a very common condition we see in our clinics every day. Researching innovative therapies like Freesolve™ RMS is critical to advancing care for our patients.” The BIOMAG™-III Study is a randomized controlled trial (RCT). The study will enroll 1,859 patients and compare Freesolve™ RMS to Xience™ Drug-Eluting Stent (DES) with respect to Target Lesion Failure (TLF) ratea at 12 months. The study will include scaffold lengths up to 40mm. The BIOMAG™-III Study will be conducted at up to 120 sites worldwide, including up to 60 sites in the U.S., underlining Teleflex’s strong global commitment to advancing resorbable scaffold technology. Furthermore, enrollment recently completed ahead of schedule for the BIOMAG™-II Study (NCT05540223). This study enrolled 1,861 patients across 20 countries in Europe and Asia Pacific. The BIOMAG™-II Study is a prospective, international, multi-center, RCT comparing Freesolve™ RMS with Xience™ DES with respect to TLF ratea at 12 months. Completion of enrollment marks a major milestone for the first large-scale, head-to-head RCT evaluating Freesolve™ RMS against DES. Additionally, Teleflex recently announced positive long-term data from the BIOMAG™-I First-In-Human (FIH) Study (NCT04157153), demonstrating 3.5% TLFb at four years and no new clinical events between two and four years for Freesolve™ RMS1. “The BIOMAG™-III Study represents an important milestone in the evolution of resorbable technologies,” said Dr. David E. Kandzari?, U.S. National Principal Investigator for the BIOMAG™-III Study, Chief, Piedmont Heart Institute, and Chief Scientific Officer, Piedmont Healthcare. “Freesolve™ RMS technology has shown positive outcomes in the BIOMAG™-I FIH trial, with a plateauing of clinical events after resorption. This has long been the vision of resorbable scaffolds.” Freesolve™ RMS is engineered to resorb within 12 months2, potentially reducing long-term events associated with permanent metallic implants. The BIOMAG™-III Study aims to generate pivotal evidence required to bring this technology to physicians and patients. “The BIOMAG™-III Study is a pivotal trial designed not only to meet rigorous regulatory standards, but also to demonstrate the long-term safety and efficacy of a fully resorbable magnesium scaffold for patients, physicians, and healthcare systems,” says Prof. Dr. Georg Nollert, Vice President Medical Affairs at Teleflex. “We believe Freesolve™ RMS has the potential to reshape the coronary intervention landscape, and the BIOMAG™-III Study could be the catalyst to drive that.” About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in the world of healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com. Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Teleflex, the Teleflex logo, Arrow, Barrigel, BIOMAG, Deknatel, Freesolve, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates in the U.S. and/or other countries. All other trademarks marked with a ™ are the property of their respective owners and are solely used for identification purposes and do not imply any affiliation, endorsement, or ownership by Teleflex Incorporated or its affiliates. Information in this material is not a substitute for the product Instructions for Use. Not all products may be available in all countries.
© 2026 Teleflex Incorporated. All rights reserved. MC-012134 Rev 0. References: Torzewski, J. Lessons from the long-term DES data: how they can inform today's practice - BIOMAG-I: 4-Year Clinical Outcomes of the Resorbable Magnesium Scaffold-DREAMS 3G. pcronline.com Published May 20, 2026. Accessed June 3, 2026. https://www.pcronline.com/Cases-resources-images/Resources/Course-videos-slides/2026/EuroPCR/Lessons-from-the-long-term-DES-data-how-they-can-inform-today-s-practice?auth=true. Research sponsored by Teleflex. Seguchi, M., Aytekin, A., Xheoa, E. et al. Vascular response following implantation of the third-generation drug-eluting resorbable coronary magnesium scaffold: an intravascular imaging analysis of the BIOMAG-I first-in-human study. EuroIntervention. 2024; 20(18): e1173-e1183. doi: 10.4244/EIJ-D-24-00055. Scaffold 99.0% resorbed at 12 months (markers are not resorbable). Research sponsored by Teleflex. Disclaimers: a For BIOMAG™-III and BIOMAG™-II Studies, TLF is a composite of Cardiac Death, Target Vessel Q-wave or non-Q wave Myocardial Infarction, or clinically driven Target Lesion Revascularization (TLR).
b For BIOMAG™-I Study, TLF is a composite of Target-Vessel Myocardial Infarction (TV-MI), clinically driven Target Lesion Revascularization (CD-TLR) and Cardiac Death. BIOMAG™-I FIH Study data is based on Kaplan-Meier failure estimate analysis. ?Drs. Waksman and Kandzari are paid consultants of Teleflex. CAUTION—Investigational device. Limited by the United States law to investigational use.
Freesolve™ RMS is clinically often referred to as DREAMS 3G RMS.
Freesolve™ RMS is not approved for sale in the United States and is commercially available in CE-mark accepting countries only. Indications for Use may vary by geographic location. View source version on businesswire.com: https://www.businesswire.com/news/home/20260623597311/en/ Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development

Four-Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long-Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)June 9, 2026 6:30 AM
Business Wire Persistently Low Target Lesion Failure and No New Cardiac-Related Event Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the four-year follow-up data from the First-in-Human BIOMAG™-I Clinical Study (NCT04157153)* presented at the EuroPCR conference in Paris, France by Prof. Jan Torzewski (Klinikverbund Allgäu, Germany). Conducted exclusively across European centers and enrolling 116 patients, the study continues to demonstrate a favorable long-term safety profile1, with no new cardiac-related1 events observed between two and four years follow-up period, establishing the third-generation Freesolve™ Resorbable Magnesium Scaffold (RMS) as a valuable treatment option. Prof. Torzewski presented the results during the session “Lessons from the long-term DES data: how can they inform today’s practice,” highlighting the relevance of long-term ‘leave nothing behind’ approach with novel technologies in modern interventional cardiology. Importantly, no cardiac death1, no target-vessel myocardial infarction (TV-MI)1, and no definite or probable scaffold thrombosis1 have been observed through four years1. The target lesion failure (TLF**) rate was 3.5%1, impelled by the clinically-driven-target lesion revascularization (CD-TLR)1, of which only one event occurred beyond the resorption period of the scaffold (at 1-year)2. These findings reinforce the safety profile3, and sustained device performance3 of the Freesolve™ RMS. “These long-term BIOMAG™-I First-In-Human Study data continue to support the safety and performance of the Freesolve™ Scaffold,” said Prof. Michael Haude?, Principal Investigator of the BIOMAG™-I Study. “The absence of cardiac death, target-vessel MI, or scaffold thrombosis throughout four years, combined with the very low TLF rate, is highly promising and aligns with the vascular healing response we aim to achieve with bioresorbable technologies.” A Promising Path Toward Future Randomized Evidence The continuing favorable 4-year outcomes further support the potential of this resorbable scaffold as a viable treatment option, offering temporary mechanical support while maintaining excellent long-term safety and efficacy. “Our focus is on enabling durable clinical outcomes, so we’re delighted to see this plateau of events continuing out to 4 years,” said Prof. Dr. Georg Nollert, Vice President Medical Affairs at Teleflex. “This gives us even more confidence that RMS could be a valuable option for treating patients where the aim is to avoid a permanent implant.” These results provide a strong foundation for the ongoing BIOMAG™-II and pending BIOMAG™-III Randomized Controlled Trials, both of which will be critical in demonstrating Freesolve™ RMS as a competitive alternative to contemporary drug-eluting stents (DES). Bioresorbable scaffolds have been developed to provide temporary mechanical support, and to prevent long-term stent-related adverse events3. Freesolve™ RMS is made of the proprietary BIOmag™ Magnesium Alloy and maintains a resorption time of 12 months4. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in the world of healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com. Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. CAUTION—Investigational device. Limited by the United States law to investigational use.
Freesolve is clinically often referred to as DREAMS 3G.
Freesolve™ RMS is not for sale in the United States and is commercially available in CE-mark accepting countries only. Indications for Use may vary by geographic location. References Torzewski, J. Lessons from the long-term DES data: how they can inform today's practice - BIOMAG-I: 4-Year Clinical Outcomes of the Resorbable Magnesium Scaffold-DREAMS 3G. pcronline.com Published May 20, 2026. Accessed June 3, 2026. https://www.pcronline.com/Cases-resources-images/Resources/Course-videos-slides/2026/EuroPCR/Lessons-from-the-long-term-DES-data-how-they-can-inform-today-s-practice?auth=true. Research sponsored by Teleflex. Seguchi M. Twelve-months vessel healing profile following the novel resorbable magnesium scaffold implantation: an intravascular OCT analysis of the BIOMAG-I trial. esc365.escardio.org. Published August 27, 2023. Accessed June 3, 2026. https://esc365.escardio.org/presentation/269109. Research sponsored by Teleflex. Haude M. ?, Wlodarczak A, van der Schaaf, RJ, et al. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study. EClinicalMedicine. 2023; 59:101940. doi: 10.1016/j.eclinm.2023.101940. Research sponsored by Teleflex. Scaffold resorbs 99.3% at 12 months (markers are not resorbable), Teleflex Data on file. * BIOMAG™-I FIH Trial, ClinicalTrials.gov: NCT04157156 https://clinicaltrials.gov/study/NCT04157153?term=BIOMAG&viewType=Card&rank=2 **Target Lesion Failure (TLF) is a composite of Target-Vessel Myocardial Infarction (TV-MI), clinically driven Target Lesion Revascularization (CD-TLR) and Cardiac Death. BIOMAG™-I FIH Study data is based on Kaplan-Meier failure estimate analysis. ? Prof. Michael Haude is a paid consultant of Teleflex. Teleflex, the Teleflex logo, Arrow, Barrigel, BIOMAG, Deknatel, Freesolve, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. Refer to the Instructions for Use for a complete listing of the indications, contraindications, warnings and precautions. Information in this material is not a substitute for the product Instructions for Use. Not all products may be available in all countries. © 2026 Teleflex Incorporated. All rights reserved. MC-012098 Rev 0. View source version on businesswire.com: https://www.businesswire.com/news/home/20260609079857/en/ Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development

Teleflex Incorporated Announces Pricing of $500 Million Senior Notes OfferingJune 1, 2026 5:40 PM
Business Wire Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today that it priced its private offering of $500.0 million aggregate principal amount of 5.875% senior notes due 2032 (the “Notes”) at an issue price of 100.000%. The sale of the Notes is expected to close on June 15, 2026, subject to customary closing conditions. The Notes will be guaranteed by each of Teleflex’s existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agreement and certain other indebtedness. Teleflex intends to use the net proceeds from the offering, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027 (the “2027 Notes”). The offering of the Notes will be made in a private transaction in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), in the United States only to investors who are reasonably believed to be “qualified institutional buyers,” as that term is defined in Rule 144A under the Securities Act, or to certain non-U.S. persons in transactions outside the United States pursuant to Regulation S under the Securities Act. The Notes and the related guarantees have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This press release is not an offer to purchase or a solicitation of an offer to sell with respect to the 2027 Notes. ABOUT TELEFLEX INCORPORATED Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. Teleflex is the home of Arrow®, Barrigel®, Deknatel®, LMA®, Pilling®, QuikClot®, Rusch®, UroLift®, and Weck® - trusted brands united by a common sense of purpose. CAUTION CONCERNING FORWARD-LOOKING INFORMATION Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements about the completion of the offering of the Notes, the anticipated use of the net proceeds from the offering and the redemption of the outstanding 2027 Notes. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K filed with the SEC on February 27, 2026 and our Quarterly Report on Form 10-Q filed with the SEC on May 7, 2026, which can be obtained on the SEC’s website at http://www.sec.gov. We undertake no obligation to publicly update or revise any forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation. View source version on businesswire.com: https://www.businesswire.com/news/home/20260601989971/en/ Lawrence Keusch
Vice President, Investor Relations and Strategy Development
610-948-2836 Original: Teleflex Incorporated Announces Pricing of $500 Million Senior Notes Offering

Teleflex Incorporated Announces Private Offering of $500 Million of Senior Notes Due 2032June 1, 2026 7:45 AM
Business Wire Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today the commencement of a private offering of $500.0 million aggregate principal amount of senior notes due 2032 (the “Notes”), subject to market and other conditions. The interest rate and other terms of the Notes will be determined at pricing. The Notes will be guaranteed by each of Teleflex’s existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agreement and certain other indebtedness. Teleflex intends to use the net proceeds from the offering, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027 (the “2027 Notes”). The offering of the Notes will be made in a private transaction in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), in the United States only to investors who are reasonably believed to be “qualified institutional buyers,” as that term is defined in Rule 144A under the Securities Act, or to certain non-U.S. persons in transactions outside the United States pursuant to Regulation S under the Securities Act. The Notes and the related guarantees have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This press release is not an offer to purchase or a solicitation of an offer to sell with respect to the 2027 Notes. ABOUT TELEFLEX INCORPORATED Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. Teleflex is the home of Arrow®, Barrigel®, Deknatel®, LMA®, Pilling®, QuikClot®, Rusch®, UroLift®, and Weck® - trusted brands united by a common sense of purpose. CAUTION CONCERNING FORWARD-LOOKING INFORMATION Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements about the terms of and completion of the offering of the Notes, the anticipated use of the net proceeds from the offering and the redemption of the outstanding 2027 Notes. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K filed with the SEC on February 27, 2026 and our Quarterly Report on Form 10-Q filed with the SEC on May 7, 2026, which can be obtained on the SEC’s website at http://www.sec.gov. We undertake no obligation to publicly update or revise any forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation. View source version on businesswire.com: https://www.businesswire.com/news/home/20260601014072/en/ Lawrence Keusch
Vice President, Investor Relations and Strategy Development
610-948-2836 Original: Teleflex Incorporated Announces Private Offering of $500 Million of Senior Notes Due 2032

Teleflex Showcases New Clinical Data at Leading Urological Congresses Highlighting Patient Experience Advantages of the UroLift™ System and Long-Term Toxicity Reduction with Barrigel™ Rectal SpacerMay 21, 2026 6:30 AM
Business Wire First Head-to-Head Randomized Control Study (RCT) Reinforces Early Patient Experience Benefits and 12-month Durability of the UroLift™ System versus Rezum™1 Three-Year Data Demonstrate Sustained Reduction in Gastrointestinal Toxicity with Barrigel™ Rectal Spacer2 Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the Interventional Urology Business Unit has released new clinical data across two major urological congresses, reinforcing the value of the UroLift™ System and Barrigel™ rectal spacer in improving patient-centered outcomes across benign prostatic hyperplasia (BPH) and prostate cancer care. Teleflex Interventional Urology innovations help urologists treat medical needs while ensuring patients can recover and maintain their quality of life long after treatment. In parallel with Teleflex’s long-term strategy to significantly streamline the Teleflex business and narrow focus to the critical care and high-acuity hospital end-markets, the company’s Interventional Urology business unit continues to drive clinical value as it prepares for its divestiture in the second half of 2026. Data presented at the 2026 American Urological Association (AUA) Annual Meeting in Washington, DC. May 15 – 18 and the European Society for Radiotherapy & Oncology (ESTRO) Congress held in Stockholm May 15 – 19 highlight early patient experience following BPH treatment1 with the UroLift™ System and sustained reductions in radiation-associated toxicity for prostate cancer patients who received Barrigel™ rectal spacer.2 CLEAR RCT: First Head-to-Head Comparison of Minimally Invasive Surgical Therapies (MISTs) Demonstrates Favorable Early Patient Experience with the UroLift™ System* At AUA 2026, Dr. Bilal Chughtai**, a urologist with Northwell Health, Garden City, N.Y., presented 12-month findings from the CLEAR (Comparing UroLift™ Experience Against Rezum™) randomized controlled trial, the first prospective, multicenter, head-to-head RCT comparing MISTs for BPH.1 The study evaluated key endpoints including catheter independence, symptom improvement, patient experience, and sexual function.1 Key study endpoints of the study: Catheter independence from day three through day seven was significantly better among UroLift™ System patients compared to Rezum™ patients, with 3 percent requiring catheter versus 20 percent (p=.02) respectively1 Early patient experience was better for the UroLift™ System patients compared to Rezum™ patients1 UroLift™ System and Rezum™ subjects had similar durability through 12 months1 Patients’ sexual function† was preserved through 12 months with the UroLift™ System1 “What stands out in our CLEAR RCT study is the consistency of the early patient experience advantages with the UroLift™ System, particularly catheter independence, rapid recovery, and preservation of sexual function, which are critical factors for both patients and physicians when selecting a treatment approach,” said Dr. Bilal Chughtai**, a urologist practicing in Syosset, N.Y. Barrigel™ Rectal Spacer Three-Year Data Demonstrate Sustained Reduction in Radiation-Associated Toxicity* At ESTRO 2026, new three-year outcomes presented by Dr. Martin King** highlighted the long-term safety and effectiveness of Barrigel™ rectal spacer.2 Key endpoints of the study: Patients in the Barrigel™ rectal spacer arm of the study experienced a continued Grade 2+ toxicity benefit sustained through three years. Zero percent of the Barrigel™ rectal spacer patients experienced Grade 2+ toxicity versus 10 percent in the control arm2 Fewer patients with greater than one centimeter of apical spacing had a decline in bowel quality of life at 36 months versus control2 These results demonstrate a durable benefit for the Barrigel™ rectal spacer subjects sustained through three years, reinforcing the role of rectal spacing in protecting bowel function during and after radiation therapy.2 “The three-year data further validate the clinical value of Barrigel™ rectal spacer, demonstrating sustained and clinically meaningful reductions in gastrointestinal toxicity,” said Martin King**, MD, PhD, presenter and radiation oncologist with the Dana-Farber Brigham Cancer Center, Harvard Medical School Associate Professor of Radiation Oncology. “Reducing radiation treatment-related toxicity is essential for prostate cancer patients, and these findings support the continued adoption of rectal spacing as a standard component of care.” 2 “These data reflect our prostate health leadership and ongoing commitment to advancing evidence-based, patient-centered solutions across the urology care continuum,” said Travis Gay, President and General Manager, Interventional Urology, Teleflex. “From improving early recovery and preserving sexual function in BPH patients with the UroLift™ System to delivering durable protection against radiation-related rectal toxicity with Barrigel™ spacer, we are focused on technologies that meaningfully improve patients’ lives.” About the UroLift™ System
The UroLift™ System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older (50 years outside U.S.). The UroLift™ System permanent implants, which can be delivered during an outpatient procedure,3 relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift™ System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.4,5 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.†6-7 A study conducted over five years showed a low retreatment rate of about 2 to 3 percent per year, or a total of 13.6 percent over the course of the study, demonstrating UroLift™ System durability.8 Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.9 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift™ System) is recommended for the treatment of BPH in both the 2021 American Urological Association and 2022 European Association of Urology clinical guidelines. More than 500,000 men have been treated with the UroLift™ System in select markets worldwide.10 Learn more at www.UroLift.com. UroLift System Important Safety Information
The UroLift™ System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 45 years or older with prostates ≤100 cc. Contraindicated in men with current gross hematuria, urinary tract infection, urinary incontinence due to incompetent sphincter, and urethral conditions that prevent device insertion. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. Visit urolift.com. About Barrigel™ Rectal Spacer
Barrigel™ rectal spacer is the first and only hyaluronic acid rectal spacer that separates the prostate from the rectum to protect the rectum during radiation therapy treatment for prostate cancer.11 Barrigel™ rectal spacer is made from Non-Animal Stabilized Hyaluronic Acid (NASHA).12 Hyaluronic acid is a substance naturally present in the human body and is highly biocompatible and fully absorbable. NASHA has a proven history of safety and efficacy in a wide variety of medical applications in men, women and children worldwide.13,14 Barrigel™ rectal spacer has been proven to significantly reduce unwanted side effects from prostate cancer radiation therapy11 and is cleared for rectal spacing in the United States, Australia, and Europe.15 Barrigel™ rectal spacer is indicated for prostate cancer patients with T1-T3b disease. For more information about Barrigel™ rectal spacer, please visit https://barrigel.com/hcp/barrigel-control-matters. Barrigel™ Rectal Spacer Important Safety Information
Barrigel™ rectal spacer is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and, in creating this space, the intent is to reduce the radiation dose delivered to the anterior rectum. It is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is intended to be absorbed by the patient’s body over time. It should only be administered by qualified and properly trained physicians with experience in ultrasound guidance and injection techniques in the urogenital/pelvic area. Potential complications include but are not limited to: pain associated with the injection; needle penetration or injection of Barrigel rectal spacer into the bladder, prostate, rectal wall, rectum, urethra, or intravascularly; local inflammatory reactions; infection; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding; constipation; and rectal urgency. Contraindicated in prostate cancer patients with clinical stage T4 disease. Individual results may vary. Visit barrigel.com. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. About Interventional Urology
The Interventional Urology Business Unit is leading in prostate health by advancing clinical evidence, elevating education, and supporting physicians and patients. Our portfolio includes Barrigel™ rectal spacer for men seeking to reduce rectal side effects associated with prostate cancer radiation therapy, the UroLift™ System for men suffering from BPH symptoms, and Deflux™ injectable gel for children with grades II-V vesicoureteral reflux (VUR). Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Barrigel, Deflux, and UroLift are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2026 Teleflex Incorporated. All rights reserved. APM1495A *Studies sponsored by Teleflex. **Drs. Chughtai and King are paid consultants of Teleflex †No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study References Chughtai et al. J Urol 2026 King M, Chao M et al. Prospective Randomized Controlled Trial of Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: 3-Year Results. Presented at: European Society for Radiotherapy and Oncology 2026 Annual Congress; May 2026; Stockholm, Sweden. Proffered Paper 3623. Shore, Can J Urol 2014 Rukstalis, Prostate Cancer Prostatic Dis 2018 UroLift™ System Instructions for Use AUA BPH Guidelines 2003, 2020 McVary, Urology 2019 Roehrborn, Can J Urol 2017 Roehrborn, J Urol 2013 Management estimate based on product sales as of June 2024. Data on file. Teleflex Interventional Urology. Mariados NF, Orio PF III, King M et al. JAMA Oncol (2023)*,** Barrigel Injectable Gel Instructions for Use (2022) Svatos M, Chell E, Low DA et al. Med Phys (2024)*,** Restylane® celebrates 25 years of natural-looking results with its signature line of hyaluronic acid fillers. 2021. Data on file Teleflex. 2025 View source version on businesswire.com: https://www.businesswire.com/news/home/20260521235608/en/ Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development

Teleflex Announces Quarterly DividendMay 15, 2026 4:30 PM
Business Wire Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 30, 2026, to shareholders of record at the close of business on May 25, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260515138502/en/ Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development

Teleflex Reports First Quarter Financial Results and Full Year 2026 OutlookMay 7, 2026 6:30 AM
Business Wire Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 31, 2026. First quarter 2026 continuing operations financial summary1 Revenue from continuing operations of $548.3 million, up 32.3% compared to the prior year period, and up 5.1% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS from continuing operations of $(0.11), compared to $1.14 in the prior year period Adjusted diluted EPS from continuing operations of $1.39, compared to $1.44 in the prior year period 2026 continuing operations guidance summary1 Maintaining GAAP revenue growth guidance range of 14.40% to 15.40% Maintaining pro forma adjusted constant currency revenue growth guidance range of 4.50% to 5.50%2 Maintaining GAAP EPS from continuing operations guidance range of $2.90 to $3.20 Maintaining Adjusted diluted EPS from continuing operations guidance range to $6.25 to $6.55 Includes full year impact of stranded costs estimated to be $90 million Excludes expected benefits from transition services (“TS”) and manufacturing services (“MS”) agreements that come into effect upon closing of Strategic Divestitures, which we anticipate will fully offset stranded costs on an annualized basis Excludes impact of repurchases under previously announced $1 billion share repurchase program and expected debt paydown of ~$800 million primarily funded by closing of Strategic Divestitures "Our first-quarter performance reflects disciplined execution and meaningful progress against our transformation plan," said Stuart Randle, Teleflex's Interim President and Chief Executive Officer. "We delivered a strong start to the year, with 5.1% pro forma adjusted constant currency revenue growth year-over-year, and we continue to expect our two strategic divestitures to close in the second half of 2026. We remain committed to using the majority of the net proceeds from the sales transactions to return capital to shareholders through our $1 billion share repurchase authorization, while also reducing debt by $800 million to enhance financial flexibility and support future growth. These actions are advancing our strategy to optimize our portfolio, strengthen Teleflex's position as a focused medical technologies leader and drive long-term value creation." Mr. Randle continued, “We recently announced the appointment of Jason Weidman as President and Chief Executive Officer, effective June 8, 2026. His deep medical technology expertise and proven track record of driving growth and innovation make him well suited to lead Teleflex into its next chapter and capitalize on the opportunities ahead. Additionally, consistent with our commitment to strong governance and creating shareholder value, we announced several actions in April, including the nomination of Michael J. Tokich to our Board of Directors, the initiation of opportunistic open-market share repurchases in the second quarter and our intent to establish a new Growth and Operating Committee of the Board.” (1) Continuing operations excludes the Acute Care, Interventional Urology, and OEM businesses that were classified as discontinued operations during the fourth quarter of 2025 as a result of our entry into agreements to divest those businesses, which we refer to as the “Strategic Divestitures". (2) Pro forma adjusted constant currency revenue growth includes revenue generated by the acquired Vascular Intervention business in the prior year period, and excludes (a) revenue generated by products previously included within continuing operations that were discontinued at the end of 2025 due to a strategic realignment and (b) the impact of foreign exchange. NET REVENUE BY GLOBAL PRODUCT CATEGORY The following table provides information regarding net revenues in each of the Company's global product categories for the three months ended March 31, 2026 and the comparable prior year period on both a GAAP and pro forma adjusted constant currency basis.   Three Months Ended             March 31, 2026   March 30, 2025       % Increase / (Decrease)       Reported revenue   Adjustment   Pro Forma Adjusted Revenue   Reported revenue   Adjustment   Pro Forma Adjusted Revenue   Reported Revenue Growth   Currency Impact   Adjustment impact   Pro Forma Adjusted Constant Currency Revenue Growth Vascular Access $236.8   $—   $236.8   $219.1   $—   $219.1   8.1%   3.3%   —%   4.8% Interventional1 204.7   —   204.7   100.2   92.6   192.8   104.4%   3.1%   98.3%   3.0% Surgical2 106.8   —   106.8   95.0   (0.5)   94.5   12.4%   3.1%   (0.6)%   9.9% Consolidated1 $548.3   $—   $548.3   $414.3   $92.1   $506.4   32.3%   3.2%   24.0%   5.1% Notes: (1) Adjustments are inclusive of Vascular Intervention pro forma and discontinued product adjustments. (2) Adjustments are inclusive of discontinued product adjustments See Pro Forma Adjusted Revenue by Global Product Category table for reconciliation of adjustments. OTHER CONTINUING OPERATIONS FINANCIAL HIGHLIGHTS Depreciation expense, amortization of intangible assets and deferred financing charges for the three months ended March 31, 2026 totaled $55.2 million compared to $39.5 million for the prior year period. Total cash, cash equivalents and restricted cash equivalents at March 31, 2026 were $329.6 million compared to $402.7 million at December 31, 2025. Net accounts receivable at March 31, 2026 were $365.5 million compared to $345.6 million at December 31, 2025. Inventories at March 31, 2026 were $380.9 million compared to $404.4 million at December 31, 2025. 2026 CONTINUING OPERATIONS OUTLOOK On a GAAP basis, the Company continues to expect full year 2026 revenue growth from continuing operations of 14.40% to 15.40%, including our estimate of an approximately 0.70% positive impact of foreign exchange rate fluctuations. On a pro forma adjusted constant currency basis, the Company is maintaining full year 2026 revenue growth from continuing operations of 4.50% to 5.50%. The Company maintained its full year 2026 GAAP diluted earnings per share from continuing operations outlook range of $2.90 to $3.20. The Company continues to expect full year 2026 adjusted diluted earnings per share from continuing operations of $6.25 to $6.55. Forecasted 2026 Pro Forma Adjusted Revenue From Continuing Operations Reconciliation   2025   2026 Guidance     Low   High GAAP revenue $1,992.7   $2,280   $2,300 Vascular Intervention pro forma adjustment $199.0   —   — Discontinued product adjustment $(14.3)   —   — Italian payback measure adjustment $(9.0)   —   — Pro forma adjusted revenue $2,168.4   $2,280   $2,300 Forecasted 2026 Pro Forma Adjusted Constant Currency Revenue Percent Growth From Continuing Operations Reconciliation   Low   High Forecasted 2026 GAAP revenue growth 14.4%   15.4% Vascular Intervention pro forma adjustment 10.0%   10.0% Discontinued product adjustment (0.7)%   (0.7)% Italian payback measure adjustment (0.5)%   (0.5)% Base year adjustment (GAAP versus pro forma adjusted) 0.4%   0.4% Estimated impact of foreign currency exchange rate fluctuations 0.7%   0.7% Forecasted 2026 pro forma adjusted constant currency revenue growth 4.5%   5.5% Forecasted 2026 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation   Low   High Forecasted GAAP diluted earnings per share from continuing operations $2.90   $3.20 Restructuring and optimization items, net of tax $0.90   $0.90 Acquisition, integration and divestiture related items, net of tax $0.61   $0.61 Other items, net of tax $(0.65)   $(0.65) ERP implementation, net of tax $0.30   $0.30 MDR, net of tax $0.02   $0.02 Intangible amortization expense, net of tax $2.17   $2.17 Forecasted adjusted diluted earnings per share from continuing operations, net of tax $6.25   $6.55 CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION A webcast of Teleflex's first quarter 2026 investor conference call can be accessed live from a link on the Company's website at teleflex.com. The call will begin at 8:00 am ET on May 7, 2026. An audio replay of the investor call will be available beginning at 11:00 am ET on May 7, 2026, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The confirmation code is 69028. ADDITIONAL NOTES References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions. In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months. Pro forma adjusted revenue and pro forma adjusted constant currency revenue growth give effect to, among other things, our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025. The pro forma information is presented for informational purposes only and is not necessarily indicative of the historical results that would have occurred under our ownership and management, nor the results that may be obtained in the future. Certain financial information is presented on a rounded basis, which may cause minor differences. Segment results and commentary exclude the impact of discontinued operations. NOTES ON NON-GAAP FINANCIAL MEASURES We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as “GAAP”. In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: pro forma adjusted revenues, pro form adjusted constant currency revenue growth, and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below. Management uses these financial measures to assess Teleflex’s financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies. Pro forma adjusted revenue: This non-GAAP measure is based upon net revenues, adjusted to (i) exclude products discontinued in the year ended December 31, 2025 due to a strategic realignment; and (ii) give effect to our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025. Pro forma adjusted constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Pro forma adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends. Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends. Restructuring and optimization charges - Restructuring and optimization charges include expenses associated with discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies, integrate acquired businesses and optimize product portfolios through targeted optimization efforts. These changes include qualified restructuring costs (which may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement), restructuring related (which may include accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of a restructuring program) and product line exit charges. Impairment charges - Impairment charges, including those related to goodwill, and other assets occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results. Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; temporary financing costs directly associated with the transaction, such as bridge loan financing fees, ticking fees, and similar charges, and the impact of derivative instruments executed to hedge foreign currency exposure or other risks associated with the purchase price. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities. Separation costs - These are expenses related to the Strategic Divestitures, including activities to prepare the businesses for divestiture and maintain continuity through the separation process. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur after the transaction and related transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures have been completed. Italian payback measure - The Italian payback measure is a law that requires suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. As a result of a ruling from the Italian courts, we recognized a decrease in our reserves during the year ended December 31, 2024, of which $13.8 million related to prior years when including discontinued operations and $6.2 million on a continuing operations basis. In August 2025, the Italian Parliament enacted a modification to the previously enacted legislation that reduced the payment amounts due from the affected companies, including Teleflex, to approximately 25% of the amounts originally invoiced for the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized a $23.7 million decrease in our reserve (and corresponding increase to revenue for the year ended December 31, 2025), of which $20.1 million pertains to prior periods when including discontinued operations and $9.0 million on a continuing operations basis. The amounts do not represent normal adjustments to revenue and are nonrecurring in nature, making it difficult to contribute to a meaningful evaluation of our period over period operating performance. Other - These are discrete items that occur sporadically and can affect period-to-period comparisons. European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until December 2027 for highest-risk devices and December 2028 for lower-risk devices, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD). Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions. ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance. Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability. PRO FORMA ADJUSTED REVENUE BY GLOBAL PRODUCT CATEGORY The following table provides information regarding pro forma adjusted revenues in each of the Company's global product categories in continuing operations for the three months ended March 31, 2026 and the comparable prior year period.   Q1 2026   Q1 2025 Vascular 236.8   219.1 Interventional 204.7   100.2 Surgical 106.8   95.0 GAAP revenue 548.3   414.3 Interventional - Vascular Intervention —   95.2 Interventional - Discontinued Products —   (2.6) Surgical - Discontinued Products —   (0.5) Pro forma adjusted revenue $548.3   $506.4 Vascular 236.8   219.1 Interventional 204.7   192.8 Surgical 106.8   94.5 Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Three Months Ended March 31, 2026   Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) (Loss) Income before income taxes Income tax expense Effective income tax rate Diluted (loss) earnings per share from continuing operations GAAP Basis - Continuing Operations $548.3 56.1% 41.2% 8.1% 3.7% $(3.8) $1.0 (26.4)% $(0.11) Adjustments                   Restructuring and optimization charges (A) — 0.6 (1.4) — 5.0 28.0 4.4   0.54 Acquisition, integration and divestiture related items (B) — 1.4 (1.0) — 2.4 13.0 3.1   0.22 ERP implementation — — (0.7) — 0.7 3.9 0.7   0.07 MDR — — — (0.1) 0.1 0.4 —   0.01 Intangible amortization expense — 3.3 (2.9) — 6.2 33.9 4.6   0.66 Adjustments total — 5.3 (6.0) (0.1) 14.4 79.2 12.8   1.50 Adjusted basis $548.3 61.4% 35.2% 8.0% 18.1% $75.4 $13.8 18.3% $1.39 Three Months Ended March 30, 2025   Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis - Continuing Operations $414.3 61.7% 36.9% 6.1% 18.3% $58.8 $6.4 10.9% $1.14 Adjustments                   Restructuring and optimization charges (A) — 1.1 — — 1.5 6.0 1.0   0.11 Acquisition, integration and divestiture related items (B) — — 4.4 — (4.4) (18.1) 0.8   (0.42) ERP implementation — — (1.4) — 1.4 5.9 1.0   0.11 MDR — — — (0.2) 0.2 0.7 —   0.02 Intangible amortization expense — 3.3 (2.9) — 6.2 25.6 3.1   0.49 Tax adjustments — — — — — — 0.7   (0.01) Adjustments total — 4.4 0.1 (0.2) 4.9 20.1 6.6   0.30 Adjusted basis $414.3 66.1% 37.0% 5.9% 23.2% $78.9 $13.0 16.4% $1.44 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues. (2) Operating margin defined as Income from continuing operations before interest and taxes as a percentage of as reported and adjusted revenues.   Totals may not sum due to rounding. Tickmarks to Reconciliation Tables (A) Restructuring and optimization charges – For the three months ended March 31, 2026, pre-tax restructuring charges were $16.8 million and restructuring related charges were $11.3 million. For the three months ended March 30, 2025, pre-tax restructuring charges were $1.4 million and restructuring related charges were $4.6 million.   (B) Acquisition, integration and divestiture related items – For the three months ended March 31, 2026, these charges primarily related to the acquisition the Vascular Intervention business of BIOTRONIK SE & Co. KG, which is inclusive of inventory step-up costs of $7.8 million and acquisition and integration costs of $7.8 million, partially offset by a benefit from contingent consideration of $2.6 million. For the three months ended March 30, 2025, these charges primarily related to the pending acquisition of the Vascular Intervention business of BIOTRONIK SE & Co. KG, which is inclusive of $6.2 million of acquisition and integration costs offset by the recognition of a $22.5 million benefit related to non-designated foreign currency forward contracts. ABOUT TELEFLEX INCORPORATED As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com. CAUTION CONCERNING FORWARD-LOOKING INFORMATION This press release contains forward-looking statements, including, but not limited to, forecasted 2026 GAAP, pro forma adjusted and pro forma adjusted constant currency revenue and revenue growth and GAAP and adjusted diluted earnings per share; our estimates regarding the projected impact of foreign currency exchange rate fluctuations on our 2026 financial results; statements about the pending Strategic Divestitures, the expected timetable for completing the Strategic Divestitures and the future financial and operating performance of the company following completion of the Strategic Divestitures; statements regarding our intended use of the net proceeds from the Strategic Divestitures; and statements regarding our ability to drive durable performance and long-term value for shareholders. Actual results could differ materially from those in the forward-looking statements due to, among other things, unanticipated difficulties and expenditures in connection with integration programs; the possibility that the Strategic Divestitures do not close; unanticipated costs and length of time required to comply with legal requirements and regulatory approvals applicable to the Strategic Divestitures; customer and shareholder reaction to the Strategic Divestitures; disruption from the Strategic Divestitures that may make it more difficult to maintain business and operational relationships; significant transaction costs; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, tariffs, sovereign debt issues and international conflicts and hostilities, such as the ongoing conflicts in the Ukraine and the Middle East; public health epidemics; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation. TELEFLEX INCORPORATED CONSOLIDATED STATEMENTS OF INCOME (LOSS) (Unaudited)   Three Months Ended   March 31, 2026   March 30, 2025   (Dollars and shares in thousands, except per share) Net revenues $ 548,262     $ 414,258   Cost of goods sold   240,836       158,827   Gross profit   307,426     255,431   Selling, general and administrative expenses   226,012       152,914   Research and development expenses   44,386       25,295   Restructuring charges, separation costs and impairment charges   16,845       1,422   Income from continuing operations before interest and taxes   20,183       75,800   Interest expense   25,718       18,537   Interest income   (1,708 )     (1,488 ) (Loss) income from continuing operations before taxes   (3,827 )     58,751   Taxes on income from continuing operations   1,011       6,417   (Loss) income from continuing operations   (4,838 )     52,334   Operating (loss) income from discontinued operations   (2,643 )     50,060   Taxes on operating income from discontinued operations   673       7,392   (Loss) income from discontinued operations   (3,316 )     42,668   Net (loss) income $ (8,154 )   $ 95,002   Earnings per share:       Basic:       (Loss) Income from continuing operations $ (0.11 )   $ 1.14   (Loss) Income from discontinued operations   (0.07 )     0.94   Net (loss) income $ (0.18 )   $ 2.08   Diluted:       (Loss) Income from continuing operations $ (0.11 )   $ 1.14   (Loss) Income from discontinued operations   (0.07 )     0.93   Net (loss) income $ (0.18 )   $ 2.07   Weighted average common shares outstanding       Basic   44,257       45,782   Diluted   44,257       45,926           TELEFLEX INCORPORATED CONSOLIDATED BALANCE SHEETS (Unaudited)   March 31, 2026   December 31, 2025   (Dollars in thousands) ASSETS       Current assets       Cash and cash equivalents $ 309,411   $ 378,564 Accounts receivable, net   365,526     345,583 Inventories   380,861     404,395 Prepaid expenses and other current assets   149,808     150,678 Prepaid taxes   16,793     19,566 Current assets of discontinued operations   637,271     639,552 Total current assets   1,859,670     1,938,338 Property, plant and equipment, net   476,955     498,281 Operating lease assets   84,912     91,817 Goodwill   2,297,447     2,305,050 Intangibles assets, net   1,485,885     1,524,150 Deferred tax assets   12,206     12,593 Other assets   113,557     112,984 Non-current assets of discontinued operations   452,370     464,026 Total assets   6,783,002     6,947,239 LIABILITIES AND EQUITY       Current liabilities       Current borrowings $ 103,125   $ 100,000 Accounts payable   143,627     130,201 Accrued expenses   118,423     117,350 Payroll and benefit-related liabilities   103,345     124,769 Accrued interest   16,478     5,404 Income taxes payable   11,824     18,787 Other current liabilities   103,929     137,195 Current liabilities of discontinued operations   127,298     128,320 Total current liabilities   728,049     762,026 Long-term borrowings   2,514,268     2,541,449 Deferred tax liabilities   169,429     183,749 Noncurrent liability for uncertain tax positions   3,831     3,536 Noncurrent operating lease liabilities   68,320     84,210 Other liabilities   162,507     194,532 Non-current liabilities of discontinued operations   52,162     52,969 Total liabilities   3,698,566     3,822,471 Commitments and contingencies       Total shareholders' equity   3,084,436     3,124,768 Total liabilities and shareholders' equity $ 6,783,002   $ 6,947,239   TELEFLEX INCORPORATED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)   Three Months Ended   March 31, 2026   March 30, 2025   (Dollars in thousands) Cash flows from operating activities of continuing operations:       Net (loss) income $ (8,154 )   $ 95,002   Adjustments to reconcile net income to net cash provided by operating activities:       (Income) loss from discontinued operations   3,316       (42,668 ) Depreciation expense   19,853       13,037   Intangible asset amortization expense   33,890       25,583   Deferred financing costs and debt discount amortization expense   1,481       851   Changes in contingent consideration   (2,632 )     (1,795 ) Stock-based compensation   6,742       6,630   Gain on non-designated foreign currency forward contracts   —       (23,268 ) Deferred income taxes, net   (12,710 )     (108 ) Interest benefit on swaps designated as net investment hedges   (8,305 )     (4,239 ) Other   3,558       762   Changes in assets and liabilities, net of effects of acquisitions and disposals:       Accounts receivable   (25,005 )     (10,939 ) Inventories   16,473       (3,474 ) Prepaid expenses and other assets   3,432       (12,724 ) Accounts payable, accrued expenses and other liabilities   8,197       (17,488 ) Income taxes receivable and payable, net   6,526       2,562   Net cash provided by operating activities from continuing operations   46,662       27,724   Cash flows from investing activities of continuing operations:       Expenditures for property, plant and equipment   (18,791 )     (24,132 ) Payments for businesses and intangibles acquired, net of cash acquired   —       (90 ) Insurance settlement proceeds   —       6,307   Net payments on swaps designated as net investment hedges   (53,494 )     —   Purchase of investments   (2,500 )     (5,000 ) Net cash used in investing activities from continuing operations   (74,785 )     (22,915 ) Cash flows from financing activities of continuing operations:       Proceeds from new borrowings   —       300,000   Reduction in borrowings   (25,250 )     (49,125 ) Repurchase of common stock   —       (300,000 ) Net (payments) proceeds from share based compensation plans and related tax impacts   (4,627 )     7,348   Payments for contingent consideration   (58 )     (56 ) Dividends paid   (15,050 )     (15,191 ) Debt extinguishment, issuance and amendment fees   —       (2,500 ) Net cash used in financing activities from continuing operations   (44,985 )     (59,524 ) Cash flows from discontinued operations:       Net cash provided by operating activities   2,362       45,370   Net cash used in investing activities   (9,214 )     (5,879 ) Net cash used in discontinued operations   (6,852 )     39,491   Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents   (4,890 )     5,052   Net increase in cash, cash equivalents and restricted cash equivalents   (84,850 )     (10,172 ) Cash, cash equivalents and restricted cash equivalents at the beginning of the period   453,848       327,650   Less: Cash, cash equivalents and restricted cash of discontinued operations   (39,448 )     (35,397 ) Cash, cash equivalents and restricted cash equivalents at the end of the period $ 329,550     $ 282,081     View source version on businesswire.com: https://www.businesswire.com/news/home/20260507377859/en/ Teleflex Incorporated:
Lawrence Keusch
Vice President, Investor Relations and Strategy Development investors.teleflex.com
610-948-2836 Original: Teleflex Reports First Quarter Financial Results and Full Year 2026 Outlook

Teleflex Appoints Jason Weidman as President and CEOApril 30, 2026 6:30 AM
Business Wire
Proven Industry Leader to Guide Company’s Next Chapter of Growth and Value Creation


Teleflex Incorporated (NYSE: TFX) today announced that Jason Weidman has been appointed President and Chief Executive Officer, effective June 8, 2026. He will succeed Stuart Randle, who has been serving as Interim President and CEO since January 2026 and will continue as a member of Teleflex’s Board of Directors. Mr. Weidman is expected to join the Teleflex Board when he assumes his role as President and CEO.


Mr. Weidman is a proven medical technology leader with over 25 years of industry experience and a strong track record of building and scaling businesses globally. He joins Teleflex from Medtronic plc, where he held a number of senior leadership roles over nearly two decades, most recently serving as SVP and President, Coronary & Renal Denervation, and SVP and President, Aortic, Peripheral and Venous. In these positions, he oversaw significant growth and global expansion of multi-billion dollar revenue operating units, including the successful launch of key innovations and acquisitions.


“We’re thrilled to welcome Jason to Teleflex. Following the completion of the divestitures, Teleflex will be a fundamentally transformed company, with a portfolio focused on our core interventional, critical care and high acuity hospital markets,” said Dr. Stephen Klasko, Teleflex’s Chairman of the Board. “Jason’s medical technology expertise is closely aligned with our focused product portfolio, and his track record of driving growth, advancing product innovations and expanding global markets make him an ideal candidate to lead Teleflex’s go-forward strategy. With attractive, high-growth end markets, what will be a significantly enhanced capital structure from our intended $1 billion share buyback and $800 million debt paydown following the close of the sale transactions and an experienced and driven leadership team, we believe Teleflex will be an incredibly compelling growth story.”


“It’s an honor for me to join Teleflex at such an important inflection point and to help lead the Company into its next phase of growth,” said Mr. Weidman. “Having spent my entire career in the medical technology industry, I see a clear opportunity for Teleflex to build on its strong foundation and commitment to innovation, further shaping the future of healthcare while advancing our purpose of improving the health and quality of people’s lives.”


Dr. Klasko added, “I also want to thank Stuart for his leadership over the past four months. The Board and I are grateful for his contributions and value his continued insights and guidance as a member of our Board.”


About Jason Weidman


Mr. Weidman brings over 25 years of experience in the medical device industry. He held key leadership roles at Medtronic from 2006 – 2026, including his most recent roles of SVP and President, Coronary & Renal Denervation and SVP and President, Aortic, Peripheral and Venous, where he spearheaded strategic product innovations and market development initiatives in coronary and peripheral vascular markets. Prior to Medtronic, Mr. Weidman held roles at Thoratec Corporation.


Mr. Weidman received an MBA in Health Care Management from the Wharton School at the University of Pennsylvania, an MS in Mechanical Engineering with a concentration in Biomechanics from Stanford University and a BSE in Mechanical Engineering from the University of Michigan.


About Teleflex Incorporated


As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.


Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.


At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260430249082/en/
Teleflex

Lawrence Keusch

Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com

610-948-2836


Original: Teleflex Appoints Jason Weidman as President and CEO

Teleflex Announces First Quarter 2026 Earnings Conference Call InformationApril 23, 2026 6:30 AM
Business Wire
Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 7, 2026.


To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, teleflex.com.


An audio replay of the call will be available beginning at 11:00 a.m. Eastern Time on May 7, 2026, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028.


About Teleflex Incorporated


As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.


Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.


At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260423610617/en/
Teleflex Incorporated:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development


investors.teleflex.com

610-948-2836


Original: Teleflex Announces First Quarter 2026 Earnings Conference Call Information

Teleflex Announces Governance UpdatesApril 9, 2026 6:30 AM
Business Wire
Michael J. Tokich, Medical Technology Industry Veteran, Nominated as Independent Director; Andrew A. Krakauer Appointed Chairman of the Board Effective Following 2026 Annual Meeting


Board to Establish Growth and Operating Committee


Company to Commence Share Repurchases Ahead of Schedule


Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced several Board and governance updates, including the nomination of Michael J. Tokich to the Board of Directors, its intent to establish a new Growth and Operating Committee of the Board and its plan to commence share repurchases under the Company’s previously announced program ahead of schedule.


The announcements reflect the Board’s continued focus on strong governance and support for the Company’s strategic priorities and long-term value creation opportunities.


Board of Directors Updates


“We are thrilled to nominate Michael for election to the Teleflex Board at the 2026 Annual Meeting. He has a deep understanding of our industry and business, along with valuable experience guiding companies through periods of significant growth,” said Dr. Stephen Klasko, Chair of the Teleflex Board of Directors. “Our Board and management team are executing a clear strategy to transform our company into a more focused medical technologies leader. Michael’s expertise, including his disciplined approach to capital allocation and strategy, will be invaluable as we work to deliver long-term value for our shareholders.”


Mr. Tokich brings more than three decades of leadership experience in public company finance, medical technology and manufacturing. He previously served as Senior Vice President and Chief Financial Officer of STERIS plc (NYSE: STE), where he played a central role in shaping the company’s financial strategy, including capital allocation, mergers and acquisitions and operational transformation initiatives. During his tenure, he helped grow the company’s market capitalization from $1 billion to over $22 billion. He currently serves as a member of the Board of Directors of Mettler-Toledo International Inc. (NYSE: MTD), where he is a member of the Audit Committee.


Additionally, Dr. Stephen Klasko and John Heinmiller will conclude their respective terms at the Annual Meeting. Dr. Klasko recently accepted a new significant healthcare leadership role. Mr. Heinmiller is pursuing other professional interests.


“On behalf of the Board, I want to thank Steve and John for their meaningful contributions and steadfast dedication to Teleflex over many years and through dynamic economic and operating environments,” said interim CEO, Stu Randle. “The vast experience they brought to the Board, along with their creative thought and fresh ideas helped guide the Company through important periods of growth and transformation. We wish them all the best.”


In connection with Dr. Klasko’s departure, Andrew A. Krakauer, the chair of the Board’s Compensation Committee, has been named Chairman of the Board, effective following the Annual Meeting. Mr. Krakauer has served as a director of Teleflex since 2018. He previously served as CEO and Board member of Cantel Medical Corp. from 2009 to 2016, which was a NYSE listed provider of infection control products and services during his tenure.


Formation of Growth and Operating Committee


The Company also announced that the Board plans to establish a Growth and Operating Committee. The Committee will focus on supporting management in driving operational execution during the significant transformation underway, while also identifying growth opportunities and enhancing accountability across the organization. The members of the Committee will be appointed by the Board following the Annual Meeting.


Share Repurchase Program Update


The Company previously anticipated commencing share purchases under the existing $1 billion share repurchase authorization following the completion of the OEM, Acute Care and Interventional Urology sale transactions, which remain on track to close in the second half of 2026. The Company now expects to begin opportunistic share repurchases in the open market during the second quarter. Any such repurchases will be subject to prevailing market conditions and the Company's operating cash flow needs.


“Our Board continues to believe that Teleflex’s current stock price does not fully reflect the significance of the strategic actions underway, nor the future value we believe they will unlock,” said Dr. Klasko. “As a result, we have determined to begin repurchasing shares opportunistically in the open market in the second quarter. This announcement is consistent with our commitment to disciplined capital allocation with a focus on long-term value creation for our shareholders.”


Advisors


J.P. Morgan Securities LLC is serving as financial advisor to Teleflex, Simpson Thacher & Bartlett LLP is serving as legal advisor and Joele Frank, Wilkinson Brimmer Katcher is serving as strategic communications advisor.


About Michael J. Tokich


Mr. Tokich is a proven financial executive with more than 30 years of global business leadership experience. His background as a CFO in the healthcare and life sciences industry will enable him to provide a wide range of perspectives on financial and strategic growth initiatives and support the Board’s oversight of financial and budgeting matters, as well as the integrity of the Company’s financial statements and internal controls.


Mr. Tokich served for 18 years as SVP and CFO at STERIS plc (NYSE: STE), a leading global healthcare and life sciences provider of products and services, prior to transitioning to the role of Senior Financial Advisor in August 2025. Mr. Tokich joined STERIS in 2000 and held various senior financial roles prior to his permanent appointment as CFO in 2008. Prior to joining STERIS, Mr. Tokich served as Divisional VP and Assistant Controller at OfficeMax Inc., where he managed SEC reporting, annual audits, and financial planning for more than 950 retail locations and corporate operations. Mr. Tokich currently serves on the board of directors of Mettler-Toledo International Inc. (NYSE: MTD).


About Andrew A. Krakauer


Mr. Krakauer has been a director of Teleflex since 2018 and currently serves as Chair of the Compensation Committee. Mr. Krakauer’s extensive executive and senior management experience in the medical device industry enables him to provide valuable insights into the Company’s business strategy, acquisitions, management, operations and growth initiatives.


Prior to his retirement in October 2016, Mr. Krakauer served as CEO of Cantel Medical Corp., which was a NYSE listed provider of infection control products and services. During his 12 years at Cantel, Mr. Krakauer held various executive positions, including President and COO. He also served as CEO and a member of Cantel’s Board of Directors from 2009 to 2016. Prior to joining Cantel, Mr. Krakauer was President of the Ohmeda Medical Division of Instrumentarium Corp., a provider of medical devices, from 1998 to 2004 (Instrumentarium was acquired by General Electric Company in 2003).


About Teleflex Incorporated


As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.


Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.


At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.


Additional Information


The timing, price and actual number of shares of common stock that may be repurchased under the share repurchase authorization will depend on a variety of factors. The repurchases may occur in open market transactions, in transactions structured through investment banking institutions, in privately negotiated transactions, by direct purchases of common stock or a combination of the foregoing. The share repurchase program does not require Teleflex to repurchase shares of its common stock, and it may be discontinued, suspended or amended at any time, without prior notice.


Forward Looking Statements


Certain statements made in this press release, other than statements of historical fact, are forward-looking statements. These statements include, but are not limited to, statements related to the sales of the Company’s Acute Care, Interventional Urology and OEM businesses; the Company’s share repurchase program; the Company’s CEO search process, director succession plans and governance enhancements; the Company’s progress in achieving its overall strategic priorities; and the Company’s stock price and future financial and operating performance and outlook. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “will,” “would,” “should,” “guidance,” “potential,” “continue,” “project,” “forecast,” “confident,” “prospects” and similar expressions typically are used to identify forward-looking statements. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the Company’s business and the industry and markets in which the Company operates. These statements are not guarantees of future performance and are subject to risks and uncertainties, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements due to a number of factors, including changes in business relationships with and purchases by or from major customers or suppliers; delays or cancellations in shipments; demand for and market acceptance of new and existing products; the impact of inflation and disruptions in the Company’s global supply chain on the Company and its suppliers (particularly sole-source suppliers and providers of sterilization services), including fluctuations in the cost and availability of resins and other raw materials, as well as certain components, used in the production or sterilization of the Company’s products, transportation constraints and delays, product shortages, energy shortages or increased energy costs, labor shortages in the United States and elsewhere, and increased operating and labor costs; the Company’s inability to integrate acquired businesses into its operations, realize planned synergies and operate such businesses profitably in accordance with the Company’s expectations; the Company’s ability to manage its ongoing CEO transition; the Company’s inability to effectively execute its restructuring programs; the Company’s inability to realize anticipated savings resulting from restructuring plans and programs; the Company’s inability to complete the sales of our Acute Care, Interventional Urology and OEM businesses, the terms and timing for such transactions, the ability to satisfy any applicable conditions and the expected benefits; the impact of enacted healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, tariffs, sovereign debt issues and international conflicts and hostilities, such as the ongoing conflicts between Russia and Ukraine and in the Middle East; public health epidemics and pandemics; difficulties entering new markets; and general economic conditions. For a further discussion of the risks relating to the Company’s business, see Item 1A, Risk Factors, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent reports filed with the Securities and Exchange Commission. The Company expressly disclaims any obligation to update these forward-looking statements, except as otherwise explicitly stated by the Company or as required by law or regulation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260409762614/en/
Teleflex Incorporated:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development


investors.teleflex.com

610-948-2836


Original: Teleflex Announces Governance Updates

Teleflex Reiterates Commitment to Value Maximizing Strategies and Strong ExecutionMarch 27, 2026 12:57 PM
Business Wire
Previously Announced Sale Transactions on Track to Close in Second Half of 2026; Expecting $1.8 Billion of Net Proceeds for Buyback and Debt Paydown


Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today issued the following statement in response to the press release issued by Irenic Capital Management L.P. (“Irenic”).


The Teleflex Board of Directors and management team are committed to acting in the best interests of the Company and its shareholders. Members of the Board and management team met with Irenic at their request on March 19, 2026, to better understand their views and underscore the Company’s commitment to maximizing value for shareholders. At that meeting, Irenic demanded that Teleflex immediately announce a public strategic alternatives process within a week or Irenic would issue a public press release calling for a sale.


Irenic grossly mischaracterizes the discussions between Teleflex and Irenic, in particular the words of Teleflex’s Chairman of the Board, Dr. Stephen Klasko. Further, Irenic’s statement that “the Board has directed the Company’s advisors to refuse approaches from potential acquirors” is patently false.


Teleflex’s Board has clearly demonstrated its willingness to consider all paths that enhance value for shareholders. Teleflex has not rebuffed inbounds from potential acquirers or received proposals to acquire the Teleflex RemainCo business. However, the Board would thoroughly and thoughtfully consider any bona fide acquisition proposal in the context of the long-term value inherent in the business.


Teleflex has made demonstrable progress optimizing its portfolio and positioning the Company for long-term value creation. In July 2025, we completed the acquisition of BIOTRONIK’s Vascular Intervention business, expanding our coronary intervention portfolio and establishing a global footprint in the fast-growing peripheral intervention market. In December 2025, we announced agreements to sell the Acute Care, Interventional Urology and OEM businesses as part of our overall transformation plan, creating a more focused medical technologies leader, with a higher forward revenue CAGR, positioned to drive growth across its core critical care and high acuity hospital market, with highly complementary businesses in Vascular Access, Interventional and Surgical.


The sale transactions, which are on track to close in the second half of 2026, are expected to deliver net proceeds of approximately $1.8 billion after tax. The Company has announced that it will use these proceeds to fund a $1.0 billion share repurchase and $800 million in debt paydown – and that it will maintain a disciplined capital allocation framework. Teleflex is also making progress on its strategic priorities, which include driving durable performance and building a clearer financial profile with significant improvements in margins, interest expense and adjusted earnings per share.


The Board is focused on successfully completing the divestitures, including the efficient and effective operational separation of the businesses from Teleflex RemainCo, as well as our ongoing CEO search. Furthermore, as interim CEO, Stu Randle has worked with the management team to devise a multi-year restructuring plan that is expected to achieve approximately $50 million in annual pre-tax cost savings upon completion in mid-2028, with a portion of these cost savings to start being realized in 2026.


As Dr. Klasko conveyed to Irenic, the Board believes that the impact of these actions, including the buyback, debt paydown, restructuring, revised strategic approach and outlook for 2027, is not yet reflected in the Company’s stock price. Teleflex will continue to take decisive actions to best position the Company for success and drive enhanced value for shareholders.


J.P. Morgan Securities LLC is serving as financial advisor to Teleflex, Simpson Thacher & Bartlett LLP is serving as legal advisor and Joele Frank, Wilkinson Brimmer Katcher is serving as strategic communications advisor.


About Teleflex Incorporated


As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.


Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.


At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.


Forward Looking Statements


Certain statements made in this press release, other than statements of historical fact, are forward-looking statements. These statements include, but are not limited to, statements related to the sales of the Company’s Acute Care, Interventional Urology and OEM businesses, including the anticipated timetable for completing the sale transactions, the anticipated net proceeds from the sale transactions and the expected use of such net proceeds; statements related to the Company’s multi-year restructuring plan, including the restructuring plan’s anticipated cost savings, the timetable for completing such restructuring plan and the timetable for realizing such cost savings; and statements related to the impact of such actions, the Company’s progress in achieving its overall strategic priorities and the Company’s stock price and future financial and operating performance and outlook. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “will,” “would,” “should,” “guidance,” “potential,” “continue,” “project,” “forecast,” “confident,” “prospects” and similar expressions typically are used to identify forward-looking statements. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the Company’s business and the industry and markets in which the Company operates. These statements are not guarantees of future performance and are subject to risks and uncertainties, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements due to a number of factors, including changes in business relationships with and purchases by or from major customers or suppliers; delays or cancellations in shipments; demand for and market acceptance of new and existing products; the impact of inflation and disruptions in the Company’s global supply chain on the Company and its suppliers (particularly sole-source suppliers and providers of sterilization services), including fluctuations in the cost and availability of resins and other raw materials, as well as certain components, used in the production or sterilization of the Company’s products, transportation constraints and delays, product shortages, energy shortages or increased energy costs, labor shortages in the United States and elsewhere, and increased operating and labor costs; the Company’s inability to integrate acquired businesses into its operations, realize planned synergies and operate such businesses profitably in accordance with the Company’s expectations; the Company’s ability to manage its ongoing CEO transition; the Company’s inability to effectively execute its restructuring programs; the Company’s inability to realize anticipated savings resulting from restructuring plans and programs; the Company’s inability to complete the sales of our Acute Care, Interventional Urology and OEM businesses, the terms and timing for such transactions, the ability to satisfy any applicable conditions and the expected benefits; the impact of enacted healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, tariffs, sovereign debt issues and international conflicts and hostilities, such as the ongoing conflicts between Russia and Ukraine and in the Middle East; public health epidemics and pandemics; difficulties entering new markets; and general economic conditions. For a further discussion of the risks relating to the Company’s business, see Item 1A, Risk Factors, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent reports filed with the Securities and Exchange Commission. The Company expressly disclaims any obligation to update these forward-looking statements, except as otherwise explicitly stated by the Company or as required by law or regulation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260327022557/en/
Teleflex Incorporated:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development
investors.teleflex.com

610-948-2836


Original: Teleflex Reiterates Commitment to Value Maximizing Strategies and Strong Execution

Teleflex Announces Quarterly DividendFebruary 26, 2026 6:45 AM
Business Wire
Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable March 31, 2026, to shareholders of record at the close of business on March 6, 2026. Additional information about Teleflex can be obtained from the company’s website at teleflex.com.


About Teleflex Incorporated

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.


Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.


At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260226952246/en/
Teleflex

Lawrence Keusch

Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com

610-948-2836


Original: Teleflex Announces Quarterly Dividend

Teleflex Reports 2025 Financial Results and Full Year 2026 OutlookFebruary 26, 2026 6:30 AM
Business Wire
Announces Restructuring to Right-Size and Reduce Cost Structure Related to Announced Strategic Divestitures


Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the year ended December 31, 2025.


Full year 2025 continuing operations financial summary1



GAAP revenue from continuing operations of $1,992.7 million, up 17.2% compared to the prior year period1


Adjusted revenue from continuing operations of $1,983.7 million, up 16.3% compared to the prior year period, and up 15.4% on an adjusted constant currency basis2






GAAP diluted EPS from continuing operations of $1.31, compared to $1.21 in the prior year period



Adjusted diluted EPS from continuing operations of $6.98, compared to $6.42 in the prior year period



2026 continuing operations guidance summary1



GAAP revenue growth guidance range of 14.40% to 15.40%



Pro forma adjusted constant currency revenue growth guidance range of 4.50% to 5.50%3



GAAP EPS from continuing operations guidance range to $2.90 to $3.20



Adjusted diluted EPS from continuing operations guidance range to $6.25 to $6.55


Includes full year impact of stranded costs estimated to be $90 million



Excludes expected benefits from transition services (“TS”) and manufacturing services (“MS”) agreements that come into effect upon closing of Strategic Divestitures, which we anticipate will fully offset stranded costs on an annualized basis



Excludes impact of repurchases under previously announced $1 billion share repurchase program and expected debt paydown of ~$800 million upon closing of Strategic Divestitures






"Teleflex is in the midst of a transformation that optimizes our portfolio, creates a more focused medical technologies leader and positions our company for meaningful value creation opportunities going forward," said Stuart Randle, Teleflex's Interim President and Chief Executive Officer. "It is energizing to see how focused and committed our team has been to delivering for customers, patients, and shareholders. We have introduced financial guidance for 2026, which calls for mid-single-digit pro forma adjusted constant currency revenue growth. Our 2026 adjusted EPS outlook includes the full impact of stranded costs and excludes benefits from TS and MS agreements, share repurchase under our current $1 billion share repurchase authorization and intended debt paydown from the estimated $1.8 billion in after-tax proceeds from the strategic divestitures. We expect the TS and MS agreements to fully offset the $90 million in stranded costs on an annualized basis. Furthermore, we are already taking action on reducing expenses when the TS and MS agreements roll off in the future, and are announcing an initial restructuring plan to mitigate $48 million to $52 million of annual stranded costs resulting from the divestitures."


Mr. Randle continued, "We expect our two strategic divestitures to close in the second half of 2026 and remain committed to using the majority of the net proceeds from the transactions to return significant capital to shareholders through share repurchases, while also reducing debt to enhance our financial flexibility and support future growth and value creation. With a more streamlined portfolio and clear strategic priorities, we believe we will be well positioned to drive durable performance and long-term value for shareholders."


STRATEGIC DIVESTITURES RESTRUCTURING PLAN


In the first quarter of 2026, in connection with the Strategic Divestitures, our Board of Directors approved and we commenced a multi-year restructuring plan intended to align our global organizational structure and supply chain infrastructure amongst our remaining businesses. The right-sizing plan is designed to eliminate stranded costs, streamline global operations, and improve our long-term cost structure, primarily through workforce reductions and capital assets rationalization. These actions, some of which we expect to occur upon exit of the transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures, are expected to be substantially completed by mid-2028.


We expect to achieve annual pre-tax savings of $48 million to $52 million in connection with the restructuring plan once it is fully implemented, and we expect to begin realizing a portion of these plan-related savings in 2026.


SECOND HALF 2025 CONTINUING OPERATIONS FINANCIAL SUMMARY1


GAAP revenue growth of 30.8% compared to the prior period


Pro forma adjusted constant currency revenue growth of 4.7% compared to the prior year period, reflecting the period during 2025 in which Teleflex owned the Vascular Intervention business3


(1) Continuing operations excludes the Acute Care, Interventional Urology, and OEM businesses that were classified as discontinued operations during the fourth quarter of 2025 as a result of our entry into agreements to divest those businesses, which we refer to as the “Strategic Divestitures".


(2) Adjusted revenue excludes the impact of adjustments in our reserves related to the Italian payback measure. Refer to Notes on Non-GAAP Financial Measures for detail on the Italian payback measure.


(3) Pro forma adjusted constant currency revenue growth includes revenue generated by the acquired Vascular Intervention business in the prior year period, and excludes (a) revenue generated by products previously included within continuing operations that were discontinued at the end of 2025 due to a strategic realignment, (b) the Italian payback measure and (c) the impact of foreign exchange.


Restated historical results reflecting the Acute Care, Interventional Urology, and OEM businesses as discontinued operations for 2025 can be found in the appendix of our slides that accompany our year-end 2025 earnings conference call.


PRO FORMA ADJUSTED REVENUE BY GLOBAL PRODUCT CATEGORY


The following table provides information regarding pro forma adjusted revenues in each of the Company's global product categories in continuing operations in addition to pro forma adjusted constant currency revenues and revenue growth for specified periods in 2025.




 





 

FY 2025






 






Q4 2025






 






Q3 2025






 






Q2 2025






 






Q1 2025








Vascular





 

917.7






 






240.2






 






232.5






 






225.9






 






219.1








Interventional





 

647.8






 






217.9






 






215.9






 






113.8






 






100.2








Surgical





 

418.2






 






110.9






 






109.5






 






102.8






 






95.0








Other





 

9.0






 






—






 






9.0






 






—






 






—








GAAP revenue





 

1,992.7






 






569.0






 






566.9






 






442.5






 






414.3








Interventional - Vascular Intervention





 

199.0






 






—






 






—






 






103.8






 






95.2








Interventional - Discontinued Products





 

(12.3)






 






(1.3)






 






(5.0)






 






(3.4)






 






(2.6)








Surgical - Discontinued Products





 

(2.0)






 






(0.4)






 






(0.6)






 






(0.5)






 






(0.5)








Other - Italian payback measure





 

(9.0)






 






—






 






(9.0)






 






—






 






—








Pro forma adjusted revenue





 

$2,168.3






 






$567.3






 






$552.2






 






$542.4






 






$506.4








Vascular





 

917.7






 






240.2






 






232.5






 






225.9






 






219.1








Interventional





 

834.5






 






216.6






 






210.9






 






214.2






 






192.8








Surgical





 

416.1






 






110.5






 






108.8






 






102.3






 






94.5








Other





 

—






 






—






 






—






 






—






 






—









 





 

Pro Forma Adjusted Constant Currency Revenue Growth








 





 

2H 2025






 






Q4 2025






 






Q3 2025








Vascular





 

2.4%






 






3.4%






 






1.4%








Interventional





 

8.1%






 






8.2%






 






8.0%








Surgical





 

3.2%






 






(0.7)%






 






7.5%








Pro forma adjusted revenue





 

4.7%






 






4.3%






 






5.0%







Reconciliation of Revenues (Dollars in millions)




 





 

Year Ended








 





 

December 31, 2025








GAAP revenue including discontinued operations





 

$3,297.0








Discontinued operations





 

(1,304.3)








Continuing operations





 

1,992.7








Italian payback measure adjustment





 

(9.0)








Adjusted revenues from continuing operations





 

$1,983.7







OTHER CONTINUING OPERATIONS FINANCIAL HIGHLIGHTS



Depreciation expense, amortization of intangible assets and deferred financing charges for the year ended December 31, 2025 totaled $182.4 million compared to $164.9 million for the prior year period.



Total cash, cash equivalents and restricted cash equivalents at December 31, 2025 were $402.7 million compared to $285.3 million at December 31, 2024.



Net accounts receivable at December 31, 2025 were $345.6 million compared to $226.7 million at December 31, 2024.



Inventories at December 31, 2025 were $404.4 million compared to $306.8 million at December 31, 2024.



2026 CONTINUING OPERATIONS OUTLOOK


On a GAAP basis, the Company expects full year 2026 revenue growth from continuing operations of 14.40%% to 15.40%%, including our estimate of an approximately 0.70% positive impact of foreign exchange rate fluctuations. On a pro forma adjusted constant currency basis, the Company expects full year 2026 revenue growth from continuing operations of 4.50% to 5.50%.


Forecasted 2026 Pro Forma Adjusted Constant Currency Revenue Growth From Continuing Operations Reconciliation




 





 

2025






 






2026 Guidance








 





 

 






Low






 






High








GAAP revenue





 

$1,992.7






 






$2,280






 






$2,300








% growth





 

 






 






14.4%






 






15.4%








Vascular Intervention pro forma adjustment





 

$199.0






 






—






 






—








Discontinued product adjustment





 

$(14.3)






 






—






 






—








Italian payback measure adjustment





 

$(9.0)






 






—






 






—








Pro forma adjusted revenue





 

$2,168.3






 






$2,280






 






$2,300








% growth





 

 






 






5.1%






 






6.1%








Base year adjustment (GAAP versus pro forma adjusted)





 

 






 






0.1%






 






0.1%








% growth





 

 






 






5.2%






 






6.2%








Estimated impact of foreign currency exchange rate fluctuations





 

 






 






(0.7)%






 






(0.7)%








% pro forma adjusted constant currency revenue growth





 

 






 






4.5%






 






5.5%







The Company expects full year 2026 GAAP diluted earnings per share from continuing operations outlook of $2.90 to $3.20. The Company expects full year 2026 adjusted diluted earnings per share from continuing operations of $6.25 to $6.55.


Forecasted 2026 Pro Forma Adjusted Constant Currency Revenue Percent Growth From Continuing Operations Reconciliation




 





 

Low






 






High








Forecasted 2026 GAAP revenue growth





 

14.4%






 






15.4%








Vascular Intervention pro forma adjustment





 

10.0%






 






10.0%








Discontinued product adjustment





 

(0.7)%






 






(0.7)%








Italian payback measure adjustment





 

(0.5)%






 






(0.5)%








Base year adjustment (GAAP versus pro forma adjusted)





 

0.4%






 






0.4%








Estimated impact of foreign currency exchange rate fluctuations





 

0.7%






 






0.7%








Forecasted 2026 pro forma adjusted constant currency revenue growth





 

4.5%






 






5.5%







Forecasted 2026 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation




 





 

Low






 






High








Forecasted GAAP diluted earnings per share from continuing operations





 

$2.90






 






$3.20








Restructuring and optimization items, net of tax





 

$0.81






 






$0.81








Acquisition, integration and divestiture related items, net of tax





 

$0.76






 






$0.76








Other items, net of tax





 

$(0.65)






 






$(0.65)








ERP implementation, net of tax





 

$0.33






 






$0.33








MDR, net of tax





 

$0.03






 






$0.03








Intangible amortization expense, net of tax





 

$2.07






 






$2.07








Forecasted adjusted diluted earnings per share from continuing operations, net of tax





 

$6.25






 






$6.55







CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION


A webcast of Teleflex's year-end 2025 investor conference call can be accessed live from a link on the Company's website at teleflex.com. The call will begin at 8:00 am ET on February 26, 2026.


An audio replay of the investor call will be available beginning at 11:00 am ET on February 26, 2026, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The confirmation code is 69028.


ADDITIONAL NOTES


References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions.


In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months.


Certain financial information is presented on a rounded basis, which may cause minor differences. Segment results and commentary exclude the impact of discontinued operations.


NOTES ON NON-GAAP FINANCIAL MEASURES


We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as “GAAP”. In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: adjusted revenue, adjusted constant currency revenue growth, pro forma adjusted revenues, pro form adjusted constant currency revenue growth, and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below. Management uses these financial measures to assess Teleflex’s financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.


Tables reconciling changes in historical adjusted constant currency net revenues and adjusted net revenues to historical GAAP net revenues and historical adjusted diluted earnings per share from continuing operations to historical GAAP diluted earnings per share from continuing operations are set forth below.


Adjusted revenue: This non-GAAP measure is based upon net revenues, adjusted to exclude the impact of adjustments in our reserves and the corresponding revenue impact related to the Italian payback measure. The Italian payback measure is a law that requires suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year.


As a result of a ruling from the Italian courts, we recognized a decrease in our reserves during the year ended December 31, 2024, of which $13.8 million related to prior years when including discontinued operations and $6.2 million on a continuing operations basis.


In August 2025, the Italian Parliament enacted a modification to the previously enacted legislation that reduced the payment amounts due from the affected companies, including Teleflex, to approximately 25% of the amounts originally invoiced for the years 2015 through 2018. Payment of the reduced amount precludes the pursuit of further legal action related to the obligation to pay the amounts relating to such years. During the third quarter of 2025, we remitted payment to the related regions to settle the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized a $23.7 million decrease in our reserve (and corresponding increase to revenue for the three months and year ended December 31, 2025), of which $20.1 million pertains to prior periods when including discontinued operations and $9.0 million on a continuing operations basis.


The amounts do not represent normal adjustments to revenue and are nonrecurring in nature, making it difficult to contribute to a meaningful evaluation of our period over period operating performance. Accordingly, management has excluded the $9.0 million favorable adjustment recognized in the current period and the unfavorable adjustment of $6.2 million in the prior period.


Adjusted constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.


Pro forma adjusted revenue: This non-GAAP measure is based upon net revenues, adjusted to (i) exclude, depending on the period presented, the impact of adjustments in our reserves and the corresponding revenue impact related to the Italian payback measure described in Adjusted revenue and approximately $14 million of products discontinued in the year ended December 31, 2025 due to a strategic realignment; and (ii) include revenues for the six months ended June 29, 2025 generated by the Vascular Intervention business we acquired from BIOTRONIK SE & Co. KG.


Pro forma adjusted constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Pro forma adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.


Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.


Restructuring and optimization charges - Restructuring and optimization charges include expenses associated with discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies, integrate acquired businesses and optimize product portfolios through targeted optimization efforts. These changes include qualified restructuring costs (which may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement), restructuring related (which may include accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of a restructuring program) and product line exit charges.


Impairment charges - Impairment charges, including those related to goodwill, and other assets occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.


Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; temporary financing costs directly associated with the transaction, such as bridge loan financing fees, ticking fees, and similar charges, and the impact of derivative instruments executed to hedge foreign currency exposure or other risks associated with the purchase price. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.


Separation costs - These are expenses related to the Strategic Divestitures, including activities to prepare the businesses for divestiture and maintain continuity through the separation process. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur after the transaction and related transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures have been completed.


Italian payback measure - These adjustments represent the exclusion of adjustments in our reserves related to the Italian payback measure as described in Adjusted revenue.


Other - These are discrete items that occur sporadically and can affect period-to-period comparisons.


Pension termination and related charges - These adjustments represent charges associated with the planned termination of the Teleflex Incorporated Retirement Income Plan, a frozen U.S. defined benefit pension plan, and related direct incremental expenses including certain charges stemming from the liquidation of surplus plan assets. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur once the plan termination process has been completed. Accordingly, management has excluded these amounts to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.


European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until December 2027 for highest-risk devices and December 2028 for lower-risk devices, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD).


Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.


ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance.


Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.


Reconciliation of Revenue Growth




 





 

2H 2025






 






Q4 2025






 






Q3 2025








 





 

Reported Revenue Growth





 

Currency Impact





 

Adjustment Impact





 

Pro Forma Adjusted Constant Currency Revenue Growth





 

Reported Revenue Growth





 

Currency Impact





 

Adjustment Impact





 

Pro Forma Adjusted Constant Currency Revenue Growth





 

Reported Revenue Growth





 

Currency Impact





 

Adjustment Impact





 

Pro Forma Adjusted Constant Currency Revenue Growth








Vascular





 

4.2%






 






(1.8)%






 






—%






 






2.4%






 






5.6%






 






(2.2)%






 






—%






 






3.4%






 






2.7%






 






(1.3)%






 






—%






 






1.4%








Interventional1





 

113.4






 






(2.8)






 






(102.5)






 






8.1






 






108.7






 






(3.4)






 






(97.1)






 






8.2






 






118.5






 






(2.2)






 






(108.3)






 






8.0








Surgical2





 

4.4






 






(1.5)






 






0.3






 






3.2






 






0.6






 






(1.7)






 






0.4






 






(0.7)






 






8.4






 






(1.1)






 






0.2






 






7.5








Total Continuing Operations3





 

30.8%






 






(2.0)%






 






24.1%






 






4.7%






 






28.7%






 






(2.4)%






 






22.0%






 






4.3%






 






33.0%






 






(1.5)%






 






26.5%






 






5.0%









Notes:





 

(1) Adjustments are inclusive of Vascular Intervention pro forma and discontinued product adjustments for all periods presented








 

(2) Adjustments are inclusive of discontinued product adjustments for all periods presented








 

(3) Adjustments are inclusive of Vascular Intervention pro forma, Italian payback measure, and discontinued product adjustments for all periods presented







Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)




Three Months Ended December 31, 2025








 





 

Revenue





 

Gross margin





 

SG&A (1)





 

R&D (1)





 

Operating margin (2)





 

(Loss) Income before income taxes





 

Income tax expense





 

Effective income tax rate





 

Diluted (loss) earnings per share from continuing operations








GAAP Basis - Continuing Operations





 

$569.0





 

54.0%





 

39.1%





 

8.6%





 

2.4%





 

$(12.4)





 

$(8.9)





 

71.4%





 

$(0.08)








Adjustments





 

 





 

 





 

 





 

 





 

 





 

 





 

 





 

 





 

 








Restructuring and optimization charges (A)





 

—





 

0.7





 

—





 

—





 

4.3





 

24.3





 

3.9





 

 





 

0.46








Acquisition, integration and divestiture related items (B)





 

—





 

4.8





 

(1.9)





 

—





 

6.7





 

37.6





 

6.8





 

 





 

0.69








Separation costs





 

—





 

—





 

—





 

—





 

0.4





 

2.2





 

1.1





 

 





 

0.03








ERP implementation





 

—





 

—





 

(1.1)





 

—





 

1.1





 

6.3





 

1.2





 

 





 

0.12








MDR





 

—





 

—





 

—





 

(0.3)





 

0.2





 

1.4





 

—





 

 





 

0.03








Intangible amortization expense





 

—





 

3.3





 

(3.1)





 

—





 

6.4





 

36.7





 

4.8





 

 





 

0.72








Tax adjustments





 

—





 

—





 

—





 

—





 

—





 

—





 

1.7





 

 





 

(0.04)








Adjustments total





 

—





 

8.8





 

(6.1)





 

(0.3)





 

19.1





 

108.5





 

19.5





 

 





 

2.01








Adjusted basis





 

$569.0





 

62.8%





 

33.0%





 

8.3%





 

21.5%





 

$96.1





 

$10.6





 

11.1%





 

$1.93









Three Months Ended December 31, 2024








 





 

Revenue






 






Gross margin






 






SG&A (1)






 






R&D (1)






 






Operating margin (2)






 






Income before income taxes






 






Income tax expense






 






Effective income tax rate






 






Diluted earnings per share from continuing operations








GAAP Basis - Continuing Operations





 

$442.0






 






60.8%






 






40.3%






 






6.6%






 






11.9%






 






$35.5






 






$(0.4)






 






(1.1)%






 






$0.77








Adjustments





 

 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 








Restructuring and optimization charges (A)





 

—






 






1.0






 






—






 






—






 






3.0






 






7.6






 






1.2






 






 






 






0.14








Impairment charges





 

—






 






—






 






—






 






—






 






—






 






5.7






 






—






 






 






 






0.12








Acquisition, integration and divestiture related items (B)





 

—






 






—






 






(2.3)






 






—






 






2.3






 






10.2






 






0.5






 






 






 






0.20








Other items (C)





 

 






 






—






 






(0.2)






 






—






 






0.2






 






1.0






 






0.2






 






 






 






0.02








ERP implementation





 

—






 






—






 






(0.8)






 






—






 






0.8






 






3.5






 






0.4






 






 






 






0.07








MDR





 

—






 






—






 






—






 






(0.1)






 






0.1






 






0.4






 






—






 






 






 






0.01








Pension termination costs





 

 






 






0.6






 






(0.7)






 






(0.2)






 






1.5






 






6.5






 






1.5






 






 






 






0.11








Intangible amortization expense





 

—






 






3.4






 






(2.7)






 






—






 






6.1






 






27.3






 






2.9






 






 






 






0.52








Tax adjustments





 

—






 






—






 






—






 






—






 






—






 






—






 






2.3






 






 






 






(0.05)








Adjustments total





 

 






 






5.0






 






(6.7)






 






(0.3)






 






14.0






 






62.2






 






9.0






 






 






 






1.14








Adjusted basis





 

$442.0






 






65.8%






 






33.6%






 






6.3%






 






25.9%






 






$97.7






 






$8.6






 






8.8%






 






$1.91









Year Ended December 31, 2025








 





 

Revenue






 






Gross margin






 






SG&A (1)






 






R&D (1)






 






Operating margin (2)






 






Income before income taxes






 






Income tax expense






 






Effective income tax rate






 






Diluted (loss) earnings per share from continuing operations








GAAP Basis - Continuing Operations





 

$1,992.7






 






56.2%






 






36.1%






 






7.3%






 






5.9%






 






$24.6






 






$(34.0)






 






(138.4)%






 






$1.31








Adjustments





 

 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 








Restructuring and optimization charges (A)





 

—






 






0.9






 






—






 






—






 






2.1






 






42.6






 






6.9






 






 






 






0.81








Impairment charges





 

—






 






—






 






—






 






—






 






5.5






 






108.1






 






24.7






 






 






 






1.86








Acquisition, integration and divestiture related items (B)





 

—






 






3.5






 






1.5






 






—






 






2.0






 






40.3






 






19.1






 






 






 






0.48








Separation costs





 

—






 






—






 






—






 






—






 






0.2






 






4.8






 






1.1






 






 






 






0.08








Other items (C)





 

—






 






—






 






—






 






—






 






—






 






0.1






 






—






 






 






 






—








Italian payback measure (D)





 

(9.0)






 






(0.1)






 






0.2






 






—






 






(0.3)






 






(9.0)






 






(0.9)






 






 






 






(0.18)








ERP implementation





 

—






 






—






 






(1.0)






 






—






 






1.0






 






19.6






 






3.3






 






 






 






0.36








MDR





 

—






 






—






 






—






 






(0.2)






 






0.2






 






4.3






 






0.1






 






 






 






0.09








Intangible amortization expense





 

—






 






3.2






 






(2.9)






 






—






 






6.1






 






121.7






 






15.7






 






 






 






2.37








Tax adjustments





 

—






 






—






 






—






 






—






 






—






 






—






 






8.8






 






 






 






(0.20)








Adjustments total





 

(9.0)






 






7.5






 






(2.2)






 






(0.2)






 






16.8






 






332.5






 






78.8






 






 






 






5.67








Adjusted basis





 

$1,983.7






 






63.7%






 






33.9%






 






7.1%






 






22.7%






 






$357.1






 






$44.8






 






12.6%






 






$6.98









Year Ended December 31, 2024








 





 

Revenue






 






Gross margin






 






SG&A (1)






 






R&D (1)






 






Operating margin (2)






 






Income before income taxes






 






Income tax expense






 






Effective income tax rate






 






Diluted earnings per share from continuing operations








GAAP Basis - Continuing Operations





 

$1,699.5






 






61.0%






 






47.5%






 






6.4%






 






6.1%






 






$26.3






 






$(30.9)






 






(117.5)%






 






$1.21








Adjustments





 

 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 






 








Restructuring and optimization charges (A)





 

—






 






0.8






 






—






 






—






 






1.9






 






24.1






 






4.1






 






 






 






0.42








Impairment charges





 

—






 






—






 






—






 






—






 






—






 






7.9






 






0.5






 






 






 






0.15








Acquisition, integration and divestiture related items (B)





 

—






 






—






 






(1.1)






 






—






 






1.1






 






18.1






 






0.5






 






 






 






0.37








Other items (C)





 

—






 






—






 






(0.2)






 






—






 






0.1






 






0.9






 






0.2






 






 






 






0.02








Italian payback measure (D)





 

6.2






 






0.2






 






—






 






—






 






0.3






 






6.2






 






—






 






 






 






0.13








ERP implementation





 

—






 






—






 






(0.7)






 






—






 






0.7






 






12.7






 






1.8






 






 






 






0.23








MDR





 

—






 






—






 






—






 






(0.3)






 






0.3






 






4.6






 






—






 






 






 






0.10








Pension termination costs





 

—






 






0.2






 






(8.0)






 






—






 






8.2






 






139.6






 






58.4






 






 






 






1.73








Intangible amortization expense





 

—






 






3.5






 






(2.8)






 






—






 






6.3






 






108.8






 






11.9






 






 






 






2.06








Tax adjustments





 

—






 






—






 






—






 






—






 






—






 






—






 






0.2






 






 






 






—








Adjustments total





 

6.2






 






4.7






 






(12.8)






 






(0.3)






 






18.9






 






322.9






 






77.6






 






 






 






5.21








Adjusted basis





 

$1,705.7






 






65.7%






 






34.7%






 






6.1%






 






25.0%






 






$349.2






 






$46.7






 






13.4%






 






$6.42









Notes:





 

(1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues.








 

(2) Operating margin defined as Income from continuing operations before interest and taxes as a percentage of as reported and adjusted revenues.









 



Totals may not sum due to rounding.







Tickmarks to Reconciliation Tables


(A) Restructuring and optimization charges – For the three months ended December 31, 2025, pre-tax restructuring charges were $20.2 million, restructuring related charges were $3.5 million, and product optimization charges were $0.6 million. For the three months ended December 31, 2024, pre-tax restructuring charges were $3.3 million and restructuring related charges were $4.3 million. For the year ended December 31, 2025, pre-tax restructuring charges were $24.5 million, restructuring related charges were $15.0 million, and product optimization charges were $3.2 million. For the year ended December 31, 2024, pre-tax restructuring charges were $9.6 million and restructuring related charges were $14.5 million.


(B) Acquisition, integration and divestiture related items – For the three months ended December 31, 2025, these charges primarily related to the acquisition the Vascular Intervention business of BIOTRONIK SE & Co. KG. For the three months ended December 31, 2025, the charges include inventory step-up costs of $26.9 million and integration and acquisition costs of $10.2 million. For the year ended December 31, 2025, these charges primarily related to the acquisition the Vascular Intervention business of BIOTRONIK SE & Co. KG and changes in the estimated fair value of our contingent consideration liabilities. For the year ended December 31, 2025, the charges include inventory step-up costs of $69.0 million, acquisition and integration costs of $36.7 million, and contingent consideration costs of $16.4 million, which were partially offset by a benefit of $82.2 million related to non-designated foreign currency forward contracts entered into to economically hedge against the foreign currency exposure associated with the cash consideration required to complete the acquisition. For the three months and year ended December 31, 2024, these charges related to changes in the estimated fair value of our contingent consideration liabilities and the acquisition of Palette Life Sciences AB.


(C) Other - For the year ended December 31, 2025, other items included expenses associated with prior year tax matters.


(D) Italian payback measure – Adjustment reflects a $9.0 million favorable adjustment pertaining to amounts reserved for prior years recognized in the year ended December 31, 2025 compared to an unfavorable adjustment pertaining to amounts reserved for prior years of $6.2 million in the year ended December 31, 2024 and its impact on the adjusted basis for each Non-GAAP financial measure presented within the table.


ABOUT TELEFLEX INCORPORATED


As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.


Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.


At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.


CAUTION CONCERNING FORWARD-LOOKING INFORMATION


This press release contains forward-looking statements, including, but not limited to, forecasted 2026 GAAP, adjusted and pro forma adjusted constant currency revenue and revenue growth and GAAP and adjusted diluted earnings per share; our estimates regarding the projected impact of foreign currency exchange rate fluctuations on our 2026 financial results; statements about the pending Strategic Divestitures, the expected timetable for completing the Strategic Divestitures and the future financial and operating performance of the company following completion of the Strategic Divestitures; statements regarding our intended use of the net proceeds from the Strategic Divestitures; statements about the restructuring program associated with the Strategic Divestitures; and statements regarding our ability to drive durable performance and long-term value for shareholders. Actual results could differ materially from those in the forward-looking statements due to, among other things, unanticipated difficulties and expenditures in connection with integration programs; the possibility that the Strategic Divestitures do not close; unanticipated costs and length of time required to comply with legal requirements and regulatory approvals applicable to the Strategic Divestitures; customer and shareholder reaction to the Strategic Divestitures; disruption from the Strategic Divestitures that may make it more difficult to maintain business and operational relationships; significant transaction costs; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, tariffs, sovereign debt issues and international conflicts and hostilities, such as the ongoing conflicts in the Ukraine and the Middle East; public health epidemics; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.




TELEFLEX INCORPORATED








CONSOLIDATED STATEMENTS OF INCOME








(Unaudited)








 





 

Three Months Ended






 






Twelve Months Ended








 





 

December 31,

2025






 






December 31,

2024






 






December 31,

2025






 






December 31,

2024








 





 

(Dollars and shares in thousands, except per share)








Net revenues





 

$






568,984






 






 






$






442,010






 






 






$






1,992,713






 






 






$






1,699,546






 








Cost of goods sold





 

 






261,537






 






 






 






173,222






 






 






 






871,959






 






 






 






662,159






 








Gross profit





 

 






307,447






 






 






 






268,788






 






 






 






1,120,754






 






 






 






1,037,387






 








Selling, general and administrative expenses





 

 






222,368






 






 






 






178,141






 






 






 






720,169






 






 






 






674,520






 








Research and development expenses





 

 






48,737






 






 






 






29,200






 






 






 






144,781






 






 






 






109,021






 








Pension settlement charge





 

 






—






 






 






 






—






 






 






 






—






 






 






 






132,732






 








Restructuring charges, separation costs and impairment charges





 

 






22,468






 






 






 






9,045






 






 






 






137,431






 






 






 






17,463






 








Income from continuing operations before interest and taxes





 

 






13,874






 






 






 






52,402






 






 






 






118,373






 






 






 






103,651






 








Interest expense





 

 






28,150






 






 






 






18,658






 






 






 






100,223






 






 






 






83,513






 








Interest income





 

 






(1,854






)






 






 






(1,755






)






 






 






(6,403






)






 






 






(6,152






)








Income from continuing operations before taxes





 

 






(12,422






)






 






 






35,499






 






 






 






24,553






 






 






 






26,290






 








(Benefit) taxes on income from continuing operations





 

 






(8,870






)






 






 






(394






)






 






 






(33,977






)






 






 






(30,901






)








Income from continuing operations





 

 






(3,552






)






 






 






35,893






 






 






 






58,530






 






 






 






57,191






 








Operating (loss) income from discontinued operations





 

 






(865,655






)






 






 






(162,253






)






 






 






(1,097,174






)






 






 






48,555






 








(Benefit) taxes on operating loss from discontinued operations





 

 






(154,878






)






 






 






10,296






 






 






 






(133,004






)






 






 






36,071






 








(Loss) income from discontinued operations





 

 






(710,777






)






 






 






(172,549






)






 






 






(964,170






)






 






 






12,484






 








Net (loss) income





 

$






(714,329






)






 






$






(136,656






)






 






$






(905,640






)






 






$






69,675






 








Earnings per share:





 

 






 






 






 






 






 






 








Basic:





 

 






 






 






 






 






 






 








(Loss) income from continuing operations





 

$






(0.08






)






 






$






0.77






 






 






$






1.31






 






 






$






1.22






 








Income (loss) from discontinued operations





 

 






(16.07






)






 






 






(3.72






)






 






 






(21.61






)






 






 






0.27






 








Net (loss) income





 

$






(16.15






)






 






$






(2.95






)






 






$






(20.30






)






 






$






1.49






 








Diluted:





 

 






 






 






 






 






 






 








(Loss) income from continuing operations





 

$






(0.08






)






 






$






0.77






 






 






$






1.31






 






 






$






1.21






 








Loss from discontinued operations





 

 






(16.07






)






 






 






(3.70






)






 






 






(21.56






)






 






 






0.27






 








Net (loss) income





 

$






(16.15






)






 






$






(2.93






)






 






$






(20.25






)






 






$






1.48






 








Weighted average common shares outstanding





 

 






 






 






 






 






 






 








Basic





 

 






44,238






 






 






 






46,373






 






 






 






44,622






 






 






 






46,837






 








Diluted





 

 






44,238






 






 






 






46,619






 






 






 






44,724






 






 






 






47,094






 









TELEFLEX INCORPORATED








CONSOLIDATED BALANCE SHEETS








(Unaudited)








 

December 31, 2025






 






December 31, 2024








 





 

(Dollars in thousands)








ASSETS





 

 






 






 








Current assets





 

 






 






 








Cash and cash equivalents





 

$






378,564






 






 






$






247,852






 








Accounts receivable, net





 

 






345,583






 






 






 






226,733






 








Inventories





 

 






404,395






 






 






 






306,766






 








Prepaid expenses and other current assets





 

 






150,678






 






 






 






101,788






 








Prepaid taxes





 

 






19,566






 






 






 






3,457






 








Current assets of discontinued operations





 

 






639,552






 






 






 






584,528






 








Total current assets





 

 






1,938,338






 






 






 






1,471,124






 








Property, plant and equipment, net





 

 






498,281






 






 






 






308,461






 








Operating lease assets





 

 






91,817






 






 






 






95,714






 








Goodwill





 

 






2,305,050






 






 






 






1,992,178






 








Intangibles assets, net





 

 






1,524,150






 






 






 






1,348,420






 








Deferred tax assets





 

 






12,593






 






 






 






9,285






 








Other assets





 

 






112,984






 






 






 






100,745






 








Non-current assets of discontinued operations





 

 






464,026






 






 






 






1,771,987






 








Total assets





 

$






6,947,239






 






 






$






7,097,914






 








LIABILITIES AND EQUITY





 

 






 






 








Current liabilities





 

 






 






 








Current borrowings





 

$






100,000






 






 






$






100,000






 








Accounts payable





 

 






130,201






 






 






 






97,858






 








Accrued expenses





 

 






117,350






 






 






 






107,979






 








Payroll and benefit-related liabilities





 

 






124,769






 






 






 






101,691






 








Accrued interest





 

 






5,404






 






 






 






5,338






 








Income taxes payable





 

 






18,787






 






 






 






41,163






 








Other current liabilities





 

 






137,195






 






 






 






59,049






 








Current liabilities of discontinued operations





 

 






128,320






 






 






 






136,282






 








Total current liabilities





 

 






762,026






 






 






 






649,360






 








Long-term borrowings





 

 






2,541,449






 






 






 






1,555,871






 








Deferred tax liabilities





 

 






183,749






 






 






 






295,455






 








Noncurrent liability for uncertain tax positions





 

 






3,536






 






 






 






1,831






 








Noncurrent operating lease liabilities





 

 






84,210






 






 






 






87,958






 








Other liabilities





 

 






194,532






 






 






 






118,436






 








Non-current liabilities of discontinued operations





 

 






52,969






 






 






 






110,863






 








Total liabilities





 

 






3,822,471






 






 






 






2,819,774






 








Commitments and contingencies





 

 






 






 








Shareholders’ equity





 

 






 






 








Common shares, $1 par value Issued: 2025 — 48,197 shares; 2024 — 48,046 shares





 

 






48,197






 






 






 






48,096






 








Additional paid-in capital





 

 






815,813






 






 






 






781,184






 








Retained earnings





 

 






3,149,760






 






 






 






4,115,870






 








Accumulated other comprehensive loss





 

 






(239,468






)






 






 






(316,669






)








 





 

 






3,774,302






 






 






 






4,628,481






 








Less: Treasury stock, at cost





 

 






649,534






 






 






 






350,341






 








Total shareholders' equity





 

 






3,124,768






 






 






 






4,278,140






 








Total liabilities and shareholders' equity





 

$






6,947,239






 






 






$






7,097,914






 









TELEFLEX INCORPORATED








CONSOLIDATED STATEMENTS OF CASH FLOWS








(Unaudited)








 





 

Year Ended








 





 

December 31, 2025






 






December 31, 2024








 





 

(Dollars in thousands)








Cash flows from operating activities of continuing operations:





 

 






 






 








Net (loss) income





 

$






(905,640






)






 






$






69,675






 








Adjustments to reconcile net income to net cash provided by operating activities:





 

 






 






 








Loss (income) from discontinued operations





 

 






964,170






 






 






 






(12,484






)








Depreciation expense





 

 






56,082






 






 






 






52,754






 








Intangible asset amortization expense





 

 






121,656






 






 






 






108,780






 








Deferred financing costs and debt discount amortization expense





 

 






4,675






 






 






 






3,415






 








Gain on non-designated foreign currency forward contracts





 

 






(82,636






)






 






 






—






 








Pension settlement charge





 

 






—






 






 






 






132,732






 








Changes in contingent consideration





 

 






16,446






 






 






 






10,027






 








Asset impairments





 

 






108,117






 






 






 






7,834






 








Stock-based compensation





 

 






25,695






 






 






 






25,960






 








Deferred income taxes, net





 

 






(100,967






)






 






 






(113,207






)








Interest benefit on swaps designated as net investment hedges





 

 






(22,220






)






 






 






(17,410






)








Other





 

 






(7,608






)






 






 






13,525






 








Changes in assets and liabilities, net of effects of acquisitions and disposals:





 

 






 






 








Accounts receivable





 

 






(85,533






)






 






 






(3,603






)








Inventories





 

 






84,041






 






 






 






6,746






 








Prepaid expenses and other assets





 

 






(35,585






)






 






 






41,906






 








Accounts payable, accrued expenses and other liabilities





 

 






(8,284






)






 






 






2,346






 








Income taxes





 

 






(35,727






)






 






 






(27,114






)








Net cash provided by operating activities from continuing operations





 

 






96,682






 






 






 






301,882






 








Cash flows from investing activities of continuing operations:





 

 






 






 








Expenditures for property, plant and equipment





 

 






(95,236






)






 






 






(90,437






)








Payments for businesses and intangibles acquired, net of cash acquired





 

 






(831,857






)






 






 






(120






)








Proceeds on non-designated balance sheet hedges





 

 






82,203






 






 






 






—






 








Proceeds from sales of business and assets





 

 






6,712






 






 






 






—






 








Insurance settlement proceeds





 

 






9,447






 






 






 






—






 








Net interest proceeds on swaps designated as net investment hedges





 

 






21,078






 






 






 






27,196






 








Proceeds from sales of investments





 

 






—






 






 






 






7,300






 








Purchase of investments





 

 






(5,000






)






 






 






(7,300






)








Net cash used in investing activities from continuing operations





 

 






(812,653






)






 






 






(63,361






)








Cash flows from financing activities of continuing operations:





 

 






 






 








Proceeds from new borrowings





 

 






1,140,000






 






 






 






130,000






 








Reduction in borrowings





 

 






(153,000






)






 






 






(291,500






)








Debt extinguishment, issuance and amendment fees





 

 






(4,961






)






 






 






—






 








Repurchase of common stock





 

 






(300,000






)






 






 






(200,000






)








Net proceeds from share based compensation plans and the related tax impacts





 

 






7,167






 






 






 






3,352






 








Payments for contingent consideration





 

 






(15,505






)






 






 






(236






)








Dividends paid





 

 






(60,268






)






 






 






(63,541






)








Excise tax paid on repurchase of common stock





 

 






(1,894






)






 






 






—






 








Net cash provided by (used in) financing activities from continuing operations





 

 






611,539






 






 






 






(421,925






)








Cash flows from discontinued operations:





 

 






 






 








Net cash provided by operating activities





 

 






243,995






 






 






 






333,856






 








Net cash used in investing activities





 

 






(36,538






)






 






 






(35,997






)








Net cash provided by (used in) discontinued operations





 

 






207,457






 






 






 






297,859






 








Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents





 

 






23,174






 






 






 






(9,654






)








Net increase (decrease) in cash, cash equivalents and restricted cash equivalents





 

 






126,199






 






 






 






104,801






 








Cash, cash equivalents and restricted cash equivalents at the beginning of the year





 

 






327,649






 






 






 






222,848






 








Less: Cash, cash equivalents and restricted cash of discontinued operations





 

 






(51,168






)






 






 






(42,335






)








Cash, cash equivalents and restricted cash equivalents at the end of the year





 

$






402,680






 






 






$






285,314






 







 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260226570435/en/
Teleflex Incorporated:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development

investors.teleflex.com

610-948-2836


Original: Teleflex Reports 2025 Financial Results and Full Year 2026 Outlook